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ABSTRACT 
 
INTRATHECAL AAV9.TRASTUZUMAB FOR TUMOR PROPHYLAXIS AND TREATMENT IN A 
MURINE XENOGRAFT MODEL OF HER2+ BREAST CANCER BRAIN METASTASES 
William Thomas Rothwell 
James M. Wilson 
 
Breast cancer brain metastases (BCBM) are a deadly sequela of breast tumors that overexpress 
human epidermal growth factor receptor 2 (HER2). HER2+ BCBM affects approximately 17,000 
women in the US every year. Median survival is 10-13 months from the time of diagnosis of 
central nervous system (CNS) disease. Current therapeutic interventions are invasive, toxic, and 
largely ineffective, leaving a clear, unmet need for targeted HER2+ BCBM treatments. 
Trastuzumab(Herceptin®) is a monoclonal antibody used to treat HER2+ breast cancer 
successfully, but systemic trastuzumab cannot bypass the blood-brain barrier (BBB). To solve 
this problem, we have developed an adeno-associated virus serotype 9 (AAV9) vector to express 
trastuzumab in vivo after a single intrathecal (IT) injection. IT vector administration in an 
orthotopic Rag1-/- murine xenograft model of HER2+ BCBM led to a significant increase in 
median survival and attenuated brain tumor growth. We also report preservation of both the 
HER2 antigen specificity and the natural killer (NK) cell-associated mechanism of action of 
trastuzumab. Finally, we demonstrate increased median survival when IT AAV9.trastuzumab is 
administered as tumor treatment. Our results indicate that IT AAV9.trastuzumab may provide 
significant anti-tumor activity in patients with HER2+ BCBM. 
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CHAPTER 1 
Adeno-associated virus (AAV) 
AAV is a small, non-enveloped parvovirus of the dependoviridiae family originally 
discovered as a contaminant in laboratory cultures of adenovirus in 1965 [1]. It has a 
single-stranded DNA genome which is about 4.7 kilobases in length and contains two 
genes, rep and cap. These genes code for full-length non-structural and viral capsid 
proteins, respectively, as well as multiple splice variants of each. These genes are 
flanked by inverted tandem repeat sequences (ITRs) of 145 base pairs in length, which 
serve to prime second strand synthesis of the viral genome in a host cell. They can also 
prime transcription of viral genes. AAV is not known to cause any disease in humans 
and can infect both dividing and non-dividing cells. [2-6]  
Multiple AAV serotypes exist and are defined by differences in amino acid 
sequence of capsid proteins. Each serotype has a unique tropism for tissues in the body, 
thus allowing the engineering of AAV gene therapy vectors targeted to a particular organ 
or set of organs. The serotypes of the first nine AAVs discovered are indicated by a 
number (AAV1 or AAV2, for example). As more AAVs were discovered, this convention 
has changed to reflect the species of origin (AAVrh10 from rhesus macaques, AAVhu32 
from humans, etc.) [7-12]. 
Wild-type AAV infection begins when a virion binds to a host cell. The full 
mechanism of attachment and entry is still incompletely understood.  Recently, a pan-
AAV receptor (AAVR) for AAV binding was reported [13]. Previously, Bell et al. showed 
that gene therapy vectors derived from AAV serotype 9 (AAV9) require a terminal 
galactose residue on host cell glycoproteins for entry [14]. In any case, binding to the 
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host cell leads to endocytosis of virions. Endocytosis of virions is necessary for 
successful infection, as direct injection of virions into the cytoplasm does not lead to 
virion localization to the nucleus. After trafficking through early endosomes, virions 
escape and are translocated to the nucleus where they uncoat. The AAV genome 
remains episomal in the nucleus, forming head-to-tail concatamers. [5, 15-23] 
Whether or not AAV genomes have the ability to integrate into the host genome 
at a specific point on chromosome 19, termed AAVS1, is debated. Regardless, AAV 
infection alone is a lysogenic event. In order for wild-type AAV to replicate and complete 
a lytic cycle, coinfection with adenovirus and/or expression of required adenovirus 
proteins in the host cell is required. [5, 15-23]  
 
AAV gene therapy vectors 
 
To engineer a non-replicating AAV gene therapy vector from wild-type AAV, one 
simply replaces the rep and cap genes in the AAV genome with an expression cassette 
containing the therapeutic gene of interest (transgene) as well as necessary regulatory 
elements including an enhancer/promoter and polyadenylation signal. The ITRs are left 
intact, flanking the expression cassette. By convention, gene therapy vectors use ITR 
sequences from AAV2. Rather than relying on adenovirus coinfection to provide proteins 
required to complete the AAV life cycle, they are provided in trans. [24] 
One common method of AAV vector production involves co-transfection of 
human embryonic kidney 293 cells (HEK293) with three plasmids. One plasmid is the 
vector genome itself containing the transgene expression cassette, another contains the 
necessary adenoviral protein genes, and a third contains the capsid protein gene for the 
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desired AAV serotype. Vector genomes are packaged into the AAV capsids that self-
assemble intracellularly, and the host HEK293 cells are lysed to collect vector. 
Interestingly, HEK293 cells were first developed after transformation of embryonic 
kidney cells with sheared adenovirus DNA. Thus, HEK293 cells already possess some 
of the adenoviral proteins necessary for AAV vector production. [24] 
Self-complementary (scAAV) AAV vectors were developed as a way to speed the 
onset of transgene expression. The genomes of these vectors are engineered to skip 
second strand synthesis, since a self-complementary genome will form a double-
stranded molecule in vivo on its own. [24]  
Most humans have been infected with at least one serotype of wild-type AAV, 
likely at a young age as antibodies to AAVs have been reported in children. Infection 
with either wild-type AAV or systemic administration of an AAV vector leads to a potent 
antibody response against the capsid protein. These antibodies may simply bind to the 
capsid protein, or the antibodies may neutralize the virus/vector (termed neutralizing 
antibodies or nAbs), rendering the particle unable to transduce a host cell. nAbs may be 
specific for one AAV serotype, or they may be cross-reactive, neutralizing multiple 
serotypes. Prevalence of antibodies against different serotypes of AAV is unique to the 
serotype in question. AAV9, for example, has a nAb prevalence in humans of about 15-
30% and a binding antibody prevalence of about 45%. A person’s geographic location 
correlates with the prevalence of anti-AAV antibodies, with higher titers of nAbs 
occurring in developing countries. [25-33] 
The presence of neutralizing antibodies in a patient or laboratory animal are of 
particular concern in the field of gene therapy, as titers of neutralizing antibodies in blood 
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greater than 1:10 have been shown to prevent AAV transduction in vivo after systemic 
dosing. This would preclude either administration of gene therapy to an individual 
altogether or re-administration of an AAV vector of a given serotype to the same patient. 
Many laboratories which study AAV are employing various techniques to engineer AAVs 
to escape neutralization. It has been suggested that plasmapheresis may serve as a tool 
to temporarily lower the titer of anti-AAV antibodies in an individual before gene therapy 
vector administration, although multiple plasmapheresis sessions may be required, as a 
single session will lower a patient’s AAV nAb titer by only 2 to 3-fold. [25-33] 
 
Approved and forthcoming gene therapies 
 
Several gene therapy products have been developed which have either been 
approved by either the Federal Drug Administration (FDA) or European Medicines 
Agency (EMA) or which are in clinical trials and are expected to be approved in the near 
future. Several of these are AAV gene therapies, but others use different vectors, such 
as lentiviral vectors derived from the human immunodeficiency virus (HIV). 
The EMA approved the first gene therapy for commercial use in Europe. Glybera 
(apolipogene tiparvovec) is manufactured by uniQure based in the Netherlands. Glybera 
is an AAV1 gene therapy engineered to deliver the enzyme lipoprotein lipase (LPL) to 
patients harboring a very rare genetic deficiency of active enzyme. LPL helps to break 
down fat-laden chylomicrons which fill the blood after meals, and familial LDL deficiency 
may lead to chronic, life-threatening attacks of pancreatitis. Although Glybera 
administration was stated to have led to decreased number of pancreatitis episodes in 
patients with LPL deficiency, its true efficacy was hotly debated. To receive Glybera 
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treatment, patients are required to undergo 60 injections of the product into the 
quadriceps muscle. Its price tag proved daunting at the equivalent of 1 million USD per 
treatment. As such, uniQure announced in April 2017 that it would not seek renewal of 
Glybera marketing authorization by the EMA, allowing it to expire in October 2017. [34] 
Another AAV gene therapy developed by Spark Therapeutics, voretigene 
niparvovec (Luxturna), has shown great promise in clinical trials. Luxturna is an AAV2 
gene therapy to treat an inherited form of blindness call Leber congenital amaurosis 
(LCA). LCA can be caused by defects in several genes, one of which is RPE65, a 
protein that is expressed in retinal pigment epithelial cells and is required for normal 
visual function. Using a sub-retinal injection, AAV2 vector with an RPE65 transgene has 
been administered to LCA patients and has shown promise in restoring vision, 
particularly in younger individuals. An FDA advisory committee recommended approval 
of Luxturna in October 2017, and it is likely that it will receive FDA approval in the fourth 
quarter of 2017 or first quarter of 2018, becoming the first gene therapy for a genetic 
disease licensed in the US. [35] 
The very first gene therapy approved by the FDA is an ex vivo form of gene 
therapy called Kymriah (tisagenlecleucel) . This treatment was approved in August 2017 
and is comprised of genetically modified chimeric antigen receptor (CAR) T cells used to 
treat B cell acute lymphoblastic leukemia (ALL), an aggressive disease that kills 90% of 
patients in the first five years after diagnosis. 83% of patients treated with Kymriah 
experienced complete remissions of their disease in trials.  
To understand how Kymriah works, it is necessary to elaborate briefly upon T cell 
biology. T cells are lymphocytes which form in the bone marrow and mature in the 
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thymus. They harbor a T cell receptor protein on their cell membranes. T cell receptors 
can recognize short peptides called epitopes. Epitopes can be derived from foreign 
proteins (for example, proteins from a virus or bacterium), self-proteins, mutant self-
proteins, etc. Almost all self- reactive T cells are deleted by a complex process in the 
thymus during T cell development, although escapees can lead to autoimmunity.  
Each T cell receptor recognizes a different epitope, which must be presented to 
the T cell receptor in the context of a major histocompatibility complex (MHC) protein. 
MHCs are present on all of our nucleated cells in the form of MHCI. MHCI presents 
intracellular self- and non-self-epitopes to the periphery. By the process of cross 
presentation, MHCI may present endocytosed antigens on specialized antigen 
presenting cells, primarily dendritic cells. MHCII is present on the surface of specialized 
antigen presenting cells such as dendritic cells, macrophages, or B cells. MHC II 
presents epitopes from endocytosed antigens.  
Once a T cell encounters its cognate epitope-MHC complex on another cell, as 
well as the necessary costimulatory signals, the T cell is primed and activated to divide 
and exert effector functions. These effector functions could include killing target cells that 
express the cognate epitope of the T cell receptor. This function is mainly performed by 
cytotoxic T lymphocytes, which harbor a CD8 molecule. CD8 is costimulatory to MHCI-
associated T cell priming. T cells may also exert effector function by releasing cytokines 
and signals crucial for priming other arms of the immune response. This function is 
mainly performed by T cells which harbor a CD4 molecule. CD4 is costimulatory to 
MHCII-associated T cell priming. 
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Rather than a conventional T cell receptor, CAR T cells express a receptor with 
an extracellular domain consisting of a small antibody construct. One antibody construct 
commonly used for this purpose is the short chain variable fragment (scFv), which is 
described further in “Antibodies” in chapter 3. In the case of Kymriah, the CAR scFv is 
murine and targets the human B cell protein CD19, which is expressed on all B cells 
including B cell leukemias and lymphomas. The advantage of using an antibody 
construct in this context is that the CD19 epitope does not have to be presented to the T 
cell in the context of an MHC. Rather, it can bind directly to its epitope. Additionally, the 
membrane-associated and intracellular domains of CAR T cells are engineered to 
provide potent co-stimulatory signaling machinery for the T cell to be induced to kill the 
target B cells. Thus, these CAR T cells are designed for fast, efficient, and specific 
recognition and killing of target cells. 
 Kymriah is derived from a patient’s own T cells, which are separated in the clinic 
from peripheral blood. Rather than AAV, lentiviral vectors are used to transfer the CAR 
gene to the T cells ex vivo, resulting in integration of the CAR expression cassette into 
the T cell genome. The cells are expanded and activated in vitro, then infused back into 
the patient. CAR T cells have led to ALL remissions in patients with high-stage disease 
who have failed other therapies. However, the toxicity associated with the release of 
large amounts of cytokines in these patients has resulted in patient mortality. As such, 
the FDA approved the use of Kymriah with an extensive risk evaluation and mitigation 
strategy over the next 5 years. Additionally, patients’ healthy B cells are also targeted by 
CD19 CAR T cells, necessitating regular infusions of intravenous immunoglobulin in 
recipients. [36, 37] 
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In summary, the field of gene therapy is growing at an exponential rate. New 
therapies for diseases once considered incurable are now contenders for cutting-edge 
treatments. The emergence of AAV gene vectors has contributed to this boom, and it is 
expected the FDA will soon approve more AAV gene therapies that are currently in 
clinical trials or pre-clinical development for use in patients. 
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CHAPTER 2 
  
The blood-brain barrier and cerebrospinal fluid 
 
The blood-brain barrier (BBB) is a physiological barrier separates the central 
nervous system (CNS) from the blood. It serves to protect the brain from organisms and 
toxins that may be present in the circulation. The BBB is formed both by astrocytyes and 
endothelial cells that line blood vessels in the CNS. These endothelial cells lack the 
usual fenestrations found in vascular endothelium elsewhere in the body; rather, they 
are held together by tight and adherens junctions. Astrocytic end feet also wrap around 
these blood vessels, forming another barrier. The BBB prevents the movement of large, 
polar, or charged molecules as well as cells from entering the CNS indiscriminately. 
Transport proteins expressed at the BBB do allow specific transfer of macromolecules 
from blood to CNS, and certain immune cells can access the CNS by moving 
intracellularly through the BBB. [38-40] 
Cerebrospinal fluid (CSF) is the liquid that bathes the brain and spinal cord, 
serving both as a cushion to the brain as well as a source of nutrients and waste 
clearance for cells of the CNS. It is made from plasma that is transported by pinocytosis 
into the CNS by specialized anatomical structures such as the choroid plexus and 
ependymal cells, which are discussed below. CSF is much like plasma in composition 
except that most proteins and cells are excluded in its production. [38-40]  
Traditionally, 80% of CSF is said to be secreted by a net-like structure called the 
choroid plexus, which floats in the lateral ventricles of the brain and is formed of a layer 
of cuboidal epithelial cells held together by tight junctions which line the outside of 
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capillaries. Other sources of CSF include ependymal cells, ciliated columnar epithelial 
cells which line both the lateral ventricles and central canal of the spinal cord, and the 
brain parenchyma itself. [38-40] 
CSF flows around CNS structures and eventually joins back with venous blood at 
the one-way valve-like arachnoid granulations, also called arachnoid villi, located in the 
venous sinuses of the skull. A small portion of CSF is thought to return to venous 
circulation along the perineural spaces surrounding cranial nerves. CSF pulsates around 
CNS structures, moving with an individual’s respiration. These pulsations are thought to 
originate at the choroid plexus and also by way of the ependymal cilia.  In humans, the 
rate of CSF formation is 0.2-0.7 mL per minute, or 600-700 mL per day, and the total 
CSF volume is between 140 – 270 mL, depending on the age and sex of the individual. 
Thus, the CSF turns over rapidly. [38-40] 
 
AAV serotype 9 (AAV9)  
 
In the early 2000s, Gao et al. reported discovery of a number of new AAV 
serotypes in humans and non-human primates (NHPs) and characterization of their 
transduction patterns. A new AAV serotype, AAV9, emerged as a promising candidate 
for gene therapy in the central nervous system (CNS) due to its superior transduction of 
neurons and glial cells in vivo. AAV9 can also transduce liver, heart, and skeletal 
muscle. [10] 
Cearley and Wolfe reported the widespread pattern of AAV9 CNS transduction in 
rodents after intravenous (IV) administration of vector, suggesting that AAV9 may cross 
the blood-brain barrier (BBB). Further studies in NHPs indicated that although IV-
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administered AAV9 vectors may cross the blood-brain barrier to a small extent by way of 
an unknown mechanism, the amount of transduction in the brain itself after IV 
administration of vector is not enough to guarantee successful therapeutic efficacy of a 
gene therapy unless exceptionally large doses are used. As such, a more targeted route 
of administration (ROA) for AAV9 delivery to the CNS was in order. [41-48]  
 
Intrathecal administration of AAV9 gene therapy vectors 
 
Several groups have demonstrated that bypassing the BBB with an intrathecal 
(IT) injection of AAV9 directly into central nervous system (CNS) leads to superior 
transduction of cortical and cerebellar brain structures compared to IV AAV9 vector 
administration. Additionally, IT administration of AAV9 will not expose vector to 
neutralizing antibodies (nAbs) circulating in the blood. Thus, individuals with high titers of 
nAbs may still be eligible to receive IT AAV gene therapy.  
There are multiple ways to access the CNS for IT vector administration. One may 
inject vector directly into the brain tissue itself (intraparenchymal injection). This 
technique involves making multiple needle tracks in the brain parenchyma and releasing 
several boluses of vector as the needle is drawn back up the needle track. This may be 
the route of administration (ROA) of choice if one desires high levels of local 
transduction of small structures in the brain such as the basal ganglia. However, this 
technique would not be suitable if one desires widespread AAV transduction in the CNS 
as these intraparenchymal injections lead to poor penetration of vector into the brain 
parenchyma. In fact, the majority of transduced cells are located in the area immediately 
surrounding the needle tracks. To guarantee widespread transduction throughout the 
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cortex by intraparenchymal injection, as is accomplished by roughly 4 intraparenchymal 
injections in mice, over 100 individual needle tracks would likely need to be made in the 
human brain. Additionally, disruption of brain tissue during intraparenchymal vector 
administration can lead to the initiation of an inflammatory response in the brain. This, in 
turn, can prime potent immune responses against the vector capsid and transgene 
which can damage CNS tissue. [49-51] 
One may also inject vector directly into the cerebrospinal fluid (CSF), the fluid 
that bathes the brain and spinal cord and is contiguous with brain interstitial fluid. Vector 
thus percolates with the CSF around CNS cells leading to widespread transduction of 
structures throughout the brain. There are multiple ways by which one may access the 
CSF. A lumbar puncture (LP) would involve administering vector directly into the CSF 
surrounding the lumbar spinal cord. Intracranioventricular (ICV) administration would 
likely involve neurosurgical placement of an Ommaya reservoir, a plastic, dome-shaped 
reservoir attached to a catheter. The catheter penetrates the skull and brain 
parenchyma, and the tip of the catheter rests in one of the lateral ventricles. CSF flows 
out of the ventricles through the catheter and into the bulb portion of the reservoir, which 
sits subcutaneously outside of the skull. After placement, one simply pierces the skin 
and reservoir with a needle to access CSF. Finally, one may deliver vector by way of 
direct injection into the cisterna magna (intra-cisterna magna, ICM), an anatomical 
reservoir of CSF located directly below the occipital portion of the skull. [49, 52-55] 
AAV9 transduction in the murine CNS has been described in many publications. 
Cearley and Wolfe administered AAV9 by direct stereotaxic intraparenchymal injection of 
vector into the brains of mice that lacked a lysosomal enzyme required to break down 
long carbohydrate molecules called glycosaminoglycans. Patients with family of genetic 
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diseases called mucopolysaccharidoses can lack one of a family of these lysosomal 
enzymes, leading to toxic accumulation of glycosaminoglycans in the CNS and other 
organs of the body.  
After intraparenchymal administration of AAV9 vector, transduction of cortical 
neurons was evident in cerebral hemisphere ipsilateral to the injections, as expected. 
Interestingly, cortical structures in the hemisphere contralateral to the side of vector 
administration were also transduced. It was postulated that AAV9 was taken up by 
neurons around the injection site and trafficked by way of axons which cross the cerebral 
hemispheres, leading to enzyme expression in the contralateral hemisphere. The 
hippocampal commissure, septal nuclei, and entorhinal commissure were identified as 
candidate structures for this phenomenon, as they contain neurons that send axons to 
the contralateral hemisphere. Trafficking of AAV9 along axons was subsequently 
confirmed in later papers from the same group. [15, 56] 
Schuster et al. described transduction of AAV9 after ICV administration of 
AAV9.GFP in mice. GFP expression was widespread throughout the CNS including in 
cortical neurons and astrocytes. Specific structures observed to be transduced included 
“cranial nerve nuclei, ventral pons, cerebellar cortex, hippocampus, pituitary, choroid 
plexus, and selected nuclei of midbrain, thalamus and hypothalamus.” Interestingly, 
transduction of the enteric nervous system was also observed. [57] 
Many labs have compared administration of AAV9 vector by way of LP or by ICM 
injection in large animals, particularly in NHPs. Two reports by Samaranch et al. 
describe ICM administration of 1.8e13 genome copies (GC) of scAAV9 vector to a total 
of 4 cynomolgus macaques. The transgene expression cassette of the vector was 
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comprised of a cytomegalovirus immediate/early enhancer-promoter (CMV) and a green 
fluorescent protein (GFP) transgene (scAAV9.CMV.GFP). 3 weeks after vector 
administration, animals were euthanized and GFP was detected in CNS tissues both by 
immunohistochemistry (IHC) and immunofluorescence (IF) microscopy.  
In all animals, GFP was expressed in cells from the prefrontal to occipital cortex 
and at all levels of spinal cord. Types of cells transduced included neurons, astrocytes, 
and ependymal cells. In the earlier of the two reports, Purkinje cells in the cerebellum 
were found to have the strongest GFP expression. GFP expression was also shown to 
cluster in cells surrounding blood vessels. In the earlier report, colocalization of GFP 
expression with cell type-specific markers showed that GABAergic interneurons were 
transduced. In the later report, the authors describe sparse transduction of cells in 
spleen and liver, suggesting that vector does indeed escape from the CNS after IT 
administration, likely with CSF as it empties into the venous circulation at the arachnoid 
granulations. [44, 58] 
Grey et al. described administration of scAAV9 vector with a different promoter-
enhancer, derived from chicken beta-actin (CBh), to express GFP in ten cynomolgus 
macaques. Two of these animals received scAAV9.CBh.GFP vector by ICM 
administration, and eight received vector by LP. Most animals received 1.83e12 GC 
vector, although two animals that received LP vector were dosed at 5.5e12 GC vector. 
After four weeks, animals were euthanized, and GFP expression was detected in cells 
throughout the cortex by IHC only.  
LP vector administration led to greatest GFP expression in lumbar segments of 
spinal cord. Using quantitative PCR (qPCR) to determine number of GC in specific 
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anatomical structures, the authors indicated that ICM vector administration led to spinal 
cord transduction at a level of 0.08 GC per diploid genome (DG) while LP vector 
administration yielded only 0.02 GC/DG. This suggests that ICM administration of vector 
is a superior ROA to LP, even for spinal cord gene transfer. Interestingly, qPCR of CSF 
collected two hours after vector administration detected no vector, suggesting that the 
rapid turnover of CSF also leads to rapid vector clearance. [41] 
A pivotal report by Hinderer et al. compares ICM and LP dosing of 6 cynomolgus 
macaques with AAV9.GFP. Four animals received vector ICM, two at a dose of 2.5e12 
GC/kg and two at a dose of 5e12 GC/kg. The two animals that received vector by LP 
were dosed at 2.5e12 GC/kg. One animal also received vector IV at 2e13 GC/kg. This IV 
dose was 8-fold higher per kg body weight than the dose given to monkeys by LP and 
the lower dose administered to monkeys ICM. 
After 14 days, expression of GFP throughout the cortex and spinal cord was 
visualized by IF, and GFP-positive neurons were quantified in an automated fashion by 
software. Importantly, animals that received vector by ICM dosing showed 10- to 100-
fold higher levels of gene transfer in the cortical CNS than animals that received vector 
by LP. In fact, ICM vector administration in these animals led to better gene transfer in 
all divisions of the spinal cord than LP vector administration. Additionally, IV vector 
delivery led to similar levels of gene transfer throughout the CNS when compared to LP 
vector administration, although the IV dose was much higher. IF colocalization of cell-
type specific markers demonstrated that AAV9 vector transduced neurons and glia, 
including astrocytes. Although the number of lymphocytes in CSF increased after vector 
administration, no clinically appreciable or histological toxicity was noted in the animals 
during the course of the experiments. [49] 
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NHPs are not the only large animals used to study IT administration of AAV9 
vector, as porcine models are becoming increasingly prevalent. One report by Federici 
et al. describes LP delivery of scAAV9.CBh.GFP to twelve pigs at one of two doses, 
4.28e10 GC/kg or 1.7e11 GC/kg. Vector was administered after single level lumbar 
laminectomy and catheter placement either “locally,” as a 1.5 mL bolus at the lumbar 
level, or “diffusely,” as three 0.5 mL boluses at the cervical, thoracic, and lumbar levels 
10 cm apart.  
After four weeks, “local” administration led to greater GFP expression at lumbar 
levels of the spinal cord, greater GFP expression in spinal cord at the higher dose, and 
GFP expression in dura up to the level of the cervical spinal cord. “Diffuse” 
administration led to transduction of all segments of spinal cord, but with very little 
transduction at the low dose. qPCR analysis of DNA from various tissues showed only 
small amounts of transduction of peripheral tissues. Only IHC was used to visualize GFP 
expression, with microscopic quantification of transduced neurons performed manually. 
[59] 
Overall, these studies suggest that unless one desires to target spinal cord 
locally, ICM AAV9 vector administration leads to the most extensive transduction of 
cortical and cerebellar structures compared LP vector administration. As such, ICM is 
the most promising IT ROA for gene therapies that require widespread transduction of 
the CNS and expression of either intracellular or secreted transgenes by neurons and 
glia throughout the cortex and cerebellum.  
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When intra-cisterna magna vector administration is infeasible: The Ommaya 
reservoir versus lumbar puncture for access to cerebrospinal fluid 
 
Although ICM vector administration will likely be the preferred method of AAV9 
vector delivery for CNS gene therapies going forward, there may be instances where this 
ROA is not feasible. In these cases, an LP or Ommaya reservoir may be preferred 
methods of access to CSF. The following is an in-depth comparison of both techniques 
in terms of safety and feasibility as ROAs for gene therapy vectors targeting the CNS. 
The Ommaya reservoir was developed in 1963 by Dr. Ayub Ommaya as a way to 
provide easy, subcutaneous access to patients’ CSF to administer drugs for fungal 
meningitis [53]. Since then, it has become the method of choice to administer 
chemotherapeutic agents directly into the CSF of patients with CNS malignancies.  
As described above, the reservoir consists of a plastic, dome-shaped structure 
connected to a catheter. To insert it, neurosurgeons shave and incise skin overlying the 
non-dominant hemisphere of the brain to expose the skull. Next, a burr hole is drilled in 
the skull that is large enough to accommodate the catheter. After penetrating the dura, 
the catheter is inserted into the brain parenchyma and advanced to the ventricle. Correct 
trajectory of the catheter may be assisted by ultrasound guidance, a stereotactic frame, 
or a device such as a Ghajar Guide (Neurodynamics, Inc.) to ensure that the catheter 
travels perpendicularly relative to the plane of the patient’s skull. To confirm entry into 
the ventricle, the surgeon will test for CSF flow through the catheter. Further 
intraoperative fluoroscopic or endoscopic imaging can be used to determine the precise 
location of the catheter tip.  
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After confirming proper placement of the catheter, the reservoir is connected, 
secured to the skull with suture, and the overlying skin is closed. A computed 
tomography (CT) scan may be performed postoperatively to confirm correct placement 
of the catheter [54]. To access the reservoir, the overlaying skin is disinfected, and a 
needle and syringe is used to puncture the reservoir and withdraw CSF. According to 
one study, reservoirs have remained in place anywhere from 2 days to 4.6 years, with a 
median of 4.1 months [60]. Both pediatric and adult patients may have an Ommaya 
reservoir implanted. 
Major complications resulting from placement and access of the Ommaya 
reservoir include infection, hemorrhage, and catheter misplacement. One study reported 
that 10% of patients with an Ommaya reservoir experienced some sort of complication 
[54].  
Infections comprise a large portion of these Ommaya reservoir complications.  
Two recent retrospective case analyses surveyed reservoir infections at two separate 
institutions over a 10 and 16-year period, respectively. 5.5 [61] and 8% [62] of patients 
with Ommaya reservoirs developed a device-related infection, which falls within the 
previously reported 2-15% infection rate [63-66].  Meningitis or meningoencephalitis 
represented the majority of infections.  
Most infections occurred soon after the device was accessed (within 7 days [62] 
or 30 days [61]).  The studies also reported that 32 [61] and 40% [62] of reservoir 
infections occurred within the first month after placement.  The median number of 
reservoir punctures before infection reported in the respective studies was 3 [62] and 
5[61], although the range was broad for both studies (0-105 [61]; 2-17 [62]).  
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The most commonly isolated bacteria from CSF cultures of patients with infected 
reservoirs are normal skin flora, particularly coagulase negative staphylococci (e.g. 
Staphylococcus epidermidis) and Proprionibacterium acnes.  However, Staphylococcus 
aureus, Pseudomonas spp., enteric bacteria, mouth flora, and even Candida spp. have 
been cultured as infectious agents [61, 62]. Reported treatments for reservoir infection 
range from device removal to intravenous and/or intrathecal antibiotics [62, 67]. Patients 
have died as a result of reservoir infections [61, 62]. 
It is important to note that the majority of patients that receive Ommaya 
reservoirs do not contract an infection. One Canadian study reports that 85% of patients 
with Ommaya reservoirs had no infection within the first year post-implantation [60]. In 
addition, it is important to consider that many patients that receive Ommaya reservoirs 
are cancer patients who are likely immunosuppressed and therefore more susceptible to 
infection in general.   
Hemorrhage is a second complication resulting from reservoir placement, 
occurring in anywhere from 1-2.8% of patients [54, 60, 63]. Subarachnoid, subdural, and 
intraventricular hematomas may occur. One retrospective study indicates that two of 
three reported reservoir-related hemorrhages were fatal.  However, these deaths were 
associated with anticoagulation or development of thrombocytopenia unrelated to device 
placement [54].  
Misplacement of the reservoir catheter tip is another significant complication of 
Ommaya reservoir implantation, occurring in 2.7-12.5% of patients [54, 68, 69]. Although 
various imaging modalities can be used both intraoperatively and postoperatively to 
confirm catheter tip placement, there are multiple reports of the catheter tip piercing the 
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brain parenchyma postoperatively [70]. One study reports the death of a patient due to 
catheter advancement through the wall of the lateral ventricle, thalamus, and into the 
midbrain [60].  
Despite these morbidities, the Ommaya reservoir offers several advantages to 
patients who would receive intrathecal gene therapy.  Only one procedure is needed to 
provide CSF access for both vector administration and subsequent sampling. CSF 
access requires a simple subcutaneous needle stick. Finally, the Ommaya reservoir is 
reported to be more comfortable for patients than serial LPs [71].  
Alternatively, clinicians may use LP as a method to access the CSF for gene 
therapy. LP was first reported by Heinrich Quincke in 1891 as a method to drain CSF 
from pediatric patients who had increased intracranial pressure due to tuberculous 
meningitis [72]. Today, it is a commonly used technique in both adults and children to 
diagnose CNS infections and to identify suspected subarachnoid hemorrhages when CT 
scans are negative [55].  
To perform a LP, the patient may sit or lie on his or her side in a fetal position 
with the back and head bent forward. The clinician palpates the vertebrae of the spine to 
locate the 3rd, 4th, and/or 5th lumbar vertebrae (L3, L4, and L5), which are located below 
the termination of the spinal cord. The skin above this area is disinfected and draped, 
and local anesthesia to the skin is administered. A spinal needle is advanced between 
L3 and L4 or L4 and 5 until the CSF from the subarachnoid space begins to flow through 
the needle. Often a “pop” is felt as the needle penetrates the dura. The clinician can then 
instill medication or anesthesia or withdraw CSF for analysis. Up to 40 mL of CSF may 
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be taken from a patient, although a 8-15 mL volume is more commonly collected for 
analytic purposes [73].  
LPs are usually conducted freehand, although fluoroscopic or ultrasound 
guidance can increase the success of the procedure [74-76]. In children, LPs are 
performed using the same procedure as in adults with one exception. At birth, the 
termination of the spinal cord is located at L3, thus a patient younger than 1 year should 
receive a LP below the L2 and L3 vertebrae to avoid piercing the spinal cord [77].  
Minor complications associated with LP include post-LP spinal headache, back 
pain, radicular pain and limb numbness, and abducens nerve palsy. These sequelae 
occur with much greater frequency than the major complications that include 
hemorrhage, cerebral herniation, and epidermoid tumors [78]. 
The most common sequela of LP is the post-LP spinal headache. The onset of 
the headache is usually within 5 days of the procedure [79] and occurs commonly in the 
front-temporal or occipital regions [80]. It is exacerbated by sitting upright or standing, 
and it is ameliorated by reclining [80]. The reported incidence of spinal headache post-
LP is variable depending on the case series. One study examined several case reports 
and reported spinal headache incidence anywhere from 12-40%. This large range is due 
to several factors including the gauge of needle used to perform the LP as well as 
technique of the clinician [79]. In adults, it has been shown that using a needle with a 
smaller diameter lessens the incidence of spinal headaches, as does using a pencil-
point spinal needle rather than one with a beveled end [81-85]. These alterations do not 
lessen the incidence of spinal headache in children [86].  
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There are several proposed pathophysiological mechanisms to explain the 
etiology of the spinal headache including persistent CSF leakage from the LP access 
point, decreased CSF pressure causing tension on the pain-sensitive lining of the brain 
and CNS blood vessels, and increased vasodilatation in the brain [87, 88].  Regardless, 
the headache is usually self-limiting, with 70% of patients recovering within a week [89, 
90]. Caffeine can be taken to relieve pain and possibly decrease the duration of the 
headache [91, 92]. In cases where the headache is especially severe or abates slowly, 
an epidural blood patch or surgical closure of the hole in the dura can be employed to 
stop the headache [83, 93, 94].  
Blood in the CSF is a relatively common occurrence in CSF collection and is 
referred to as a “traumatic” or “bloody tap.”  This occurs if the spinal needle pierces an 
epidural vein [78]. Rarely, however, severe hemorrhage due to severing of subdural and 
subarachnoid vessels can lead to subarachnoid, epidural, or subdural hematomas that 
may compresses the spinal cord causing neurologic deficits and possibly death [95]. As 
is the case for patients that receive Ommaya reservoirs, patients that are anticoagulated 
after the LP procedure or who have a bleeding diathesis are at higher risk for hematoma 
post-LP [95]. If a hematoma does form in the spinal canal, it may require surgical 
decompression. Additionally, the patient may experience permanent sensory or motor 
damage [96].  
Other complications of LP include back pain and paresthesia in the lower 
extremities and groin [73]; these are relatively common during and immediately after the 
procedure. Cerebral herniation through the foramen magnum due to increased 
intracranial pressure (ICP) is a fatal complication of LP. A CT scan should thus be 
conducted for all patients exhibiting signs of increased ICP before LP is performed [73].  
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Meningitis is rarely experienced following an LP obtained for diagnostic purposes [97] 
and is usually associated with poor disinfection of skin or instruments used for the 
procedure, poor aseptic technique, or (somewhat controversially) contamination by 
mouth flora of the clinician or hospital staff performing or assisting with the LP [98]. 
Epidermoid tumors are another uncommon sequela of LP and are thought to result from 
seeding of the subarachnoid space with epidermoid tissue dislodged during the 
procedure. Most of these epidermoid tumors are discovered in early to late childhood in 
patients who received LPs as infants [78, 99, 100].  
LPs are advantageous for gene therapy applications because they do not require 
a specialist to perform. Most internal medicine or pediatric clinicians are trained to 
perform an LP. LPs are much less invasive, quicker, and cheaper than implanting an 
Ommaya reservor. In addition, the incidence of severe complications or infections for 
LPs is universally recognized to be very low. 
In order to choose the best route of administration and subsequent access to 
CSF for gene therapies in the CNS, one may consider how treatment may progress for a 
patient who undergoes Ommaya reservoir implantation versus one who receives serial 
LPs.  
In one case, the patient would undergo surgery to implant the Ommaya reservoir 
prior to vector administration. In the absence of subsequent infection, it is feasible to 
assume that vector may be instilled through the reservoir soon after recovery from the 
implantation procedure. CSF would be collected from the reservoir, perhaps at 7, 14, 30, 
60, and 90 days after vector administration to evaluate transgene expression and 
immune responses.  
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A high index of suspicion for infection would be maintained through the course of 
treatment and evaluation given the increased likelihood of infection within 7 to 30 days of 
last reservoir access. The number of reservoir taps may be increased, although this 
would exceed the 3 and 5 taps reported above as the median number of reservoir 
accesses before infection occurs.  The risk of infection may be mitigated if the patient is 
not immunocompromised due to cancer or chemotherapy treatment. Patients with a 
bleeding diathesis due to thrombocytopenia or clotting factor deficiencies would require 
close monitoring and a low threshold for CT imaging to catch hemorrhages early.  Adult 
patients or families of pediatric patients who experience great distress at the prospect of 
serial LPs or who find LPs unbearably painful or uncomfortable may decide that the 
convenience of an Ommaya reservoir outweighs its risk of morbidity and mortality. 
In the second case, the patient would receive a gene therapy vector intrathecally 
by any number of methods including but not limited to instillation through an Ommaya 
reservoir that is removed within days of treatment. The patient would then experience 
serial LPs punctures to collect CSF for transgene and immunological analysis, again 
perhaps at 7, 14, 30, 60, and 90 days post-treatment. The risk of infection due to LP for 
this patient would be low, thus clinical suspicion in response to CNS abnormalities would 
be focused on complications caused by gene therapy. The same precautions for patients 
prone to hemorrhage would be taken in this instance as described above. It is likely that 
at least one of these LPs would result in a spinal headache and back pain, both of which 
would likely dissipate within several days to a week. It is possible that the patient will 
experience radiculopathy and paresthesia during or after the procedure, and it would be 
very unlikely for the patient will develop an epidermoid tumor, abducens palsy, or 
cerebral herniation (unless, in the latter case, the gene therapy treatment leads to 
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increased ICP that is not detected before LP is performed). Overall, serial LPs would be 
relatively safe following gene therapy treatment. 
Ultimately, the factors that will determine whether the Ommaya reservoir or serial 
LPs are chosen for an individual patient or specific treatment may be further dictated by 
the expertise of the clinician and center at which therapy is initiated, the patient’s 
immune competency, the patient’s propensity to bleed, whether spinal cord cells are the 
targets of gene transfer for a given therapy, and the level of comfort the patient or his or 
her family has for either modality. 
 
 
 
 
 
 
 
 
 
26 
 
CHAPTER 3 
Antibodies 
Antibodies are proteins produced by the immune system in response to the 
introduction of proteins that the body senses as foreign. These foreign proteins could 
come from a virus, bacterium, or a transplanted organ. Each individual antibody attaches 
to a very specific region of this foreign protein. This region of binding is called an 
epitope. The epitope may be linear, composed of an adjacent sequence of 5 to 20 amino 
acids, or the epitope may be conformational, meaning that it is comprised of non-
adjacent amino acids that exist near each other in the three-dimensional confirmation of 
the protein. The protein containing these epitopes is called an antigenic protein or 
antigen. This antigen may also be another macromolecule, for example a carbohydrate 
or glycoprotein.  
Antibodies are produced by a specialized immune cell called a B cell, a 
lymphocyte of the immune system which develops and matures in the bone marrow. 
Each B cell produces an antibody that has unique specificity for a particular epitope. 
Upon exposure to its specific antigen along with costimulatory signals from other 
immune cells, B cells begin to secrete antibodies. At first, the antibodies tend to have a 
relatively low affinity for a particular antigen, meaning the strength of the attachment is 
relatively low. As time goes by, the B cells undergo a process called affinity maturation 
whereby the strength of attachment of these secreted antibodies increases due to 
random mutations specifically in the antibody gene.  
Activated B cells will divide to produce a clone of cells. Some members of this 
clone will become plasma cells, which are long-lived cells and specialized to produce a 
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large amount of antibody. As the immune response progresses and diminishes, some B 
cells become memory cells, specialized to re-activate upon secondary exposure to 
antigen and secrete antibodies again. 
Antibodies are also called immunoglobulins (Ig). There are several types of Igs 
including IgG, IgM, IgA, IgE, and IgD, each of which have structural similarity and serve 
a specific purpose in an immune response. IgM, for example, is a large, bulky molecule 
of approximately 970 kDa that is the first type of antibody secreted by a B cell when it 
encounters its antigen. IgA is shaped like two Ys connected at their stalks and is 
produced at mucosal surfaces. IgE is a Y-shaped molecule secreted in response to 
allergens. IgG is described in the next paragraph. 
After a B cell encounters its antigen and secretes IgM, the B cell undergoes a 
process called class switching and begins to secrete IgG, a 150 kDa Y-shaped Ig made 
of four polypeptide chains, two heavy and two light chains. The stalk of the Y is called 
the crystallizable fragment (Fc), and the two shorter “prongs” are each called antigen-
binding fragments (Fab). An IgG has two sites for antigen attachment, one at each end 
of the two Fabs. The sites of antigen attachment are comprised of complementarity 
determining regions (CDRs) and confer the antigen/epitope specificity of a given 
antibody. This specificity is unique to the antibodies produced by a single B cell or clone 
of B cells.  
The structure of an antibody can also be described with respect to protein 
domains or regions. An IgG is made of four types of domains, three constant domains 
comprised of the Fc plus the lower portion of the Fab and one variable domain at the 
end of the Fab prongs. The variable domain encompasses the CDRs. Constant domains 
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on the heavy chain of an IgG are numbered (CH1, CH2, CH3), with CH3 existing at the 
bottom of the stalk of the IgG. The light chain constant regions are termed CL. Variable 
regions on the heavy and light chains are called VH and VL, respectively, and the 
combined heavy and light chain variable regions are termed Fv. 
When an antigen is delivered to an individual, many B cells may be stimulated to 
produce antibodies against different parts of the antigenic protein. If one were to harvest 
these B cells, each antibody produced by different clones of B cells would have a unique 
set of CDRs, and each antibody may play one of many different functions in the 
clearance of the antigen from the body. Some antibodies may opsonize the foreign 
protein, binding to it and signaling to phagocytic cells to engulf the protein or organism 
on which the protein is found. This is called opsonization. At other times antibodies serve 
as flags to other immune cells such as natural killer (NK) cells to kill the cell harboring 
the antigen. Antibodies may also activate the complement cascade. 
The antibodies produced by a single B cell or a genetically identical clone of B 
cells are called monoclonal antibodies. These antibodies have the same amino acid 
sequence and CDRs, and they attach to the same epitope on a given protein. In 
contrast, polyclonal antibodies are antibodies all targeted against the same antigen, but 
they are produced by multiple B cells or B cell clones. The epitopes of polyclonal 
antibodies are located on many different places on the same antigenic protein. 
IgGs can be further divided into sub-classes which differ from each other slightly 
in the sequence of the Fc and their functions in the body. In humans, the four IgG 
subclasses are IgG1, IgG2, IgG3, and IgG4. Each sub-class differs in its affinity for Fc 
receptors on effector cells, complement cascade factor C1, the neonatal Fc receptor 
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(described below), etc. Fc-binding receptors are generally called Fc receptors (FcRs), 
with FcγRs being FcRs that bind to IgG as opposed to IgA (FcαRs) or IgE (FcεRs). 
Different IgG subclasses mediate different IgG effector functions. IgG1, for 
example, has a high affinity for activating FcγRs, while IgG4 has a much lower affinity for 
these receptors. As such, immune cells such as NK cells that express activating FcγRs 
will bind to the Fc region of IgG1 and be stimulated to exert their effector functions. IgG4, 
however, has low affinity for activating FcγRs, so NK cell effector function is not induced 
by IgG4. 
To make a monoclonal antibody in the laboratory, B cells are harvested from an 
individual or animal and are fused with a myeloma tumor cell to immortalize it. The 
resulting “hybridoma” cells are individually sorted into cell culture plates. They divide 
continuously forming a clone which secretes a unique monoclonal antibody into cell 
culture supernatant. The antibody can be purified from this supernatant and 
characterized in terms of its epitope and function. 
Scientists and physicians have used monoclonal antibodies for decades in 
applications from the laboratory to the clinic. The first report of production of monoclonal 
antibodies by the hybridoma method described above was in 1975 [101]. From 1980 to 
1982, monoclonal antibodies against human lymphoma-associated antigen were first 
administered to human patients to treat T cell lymphoma as well as gastrointestinal 
tumors. The Nobel Prize in Medicine was awarded in 1984 to Niels K. Jerne, Georges 
J.F. Köhler and César Milstein for “the specificity in development and control of the 
immune system" and the discovery of "the [hybridoma] principle for production of 
monoclonal antibodies.” In 1997, the FDA approved the first therapeutic monoclonal 
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antibody to treat B cell non-Hodgkin lymphomas, rituximab (Rituxan). Although the US 
patent for rituximab expired in 2015, it is still used today in the clinic. [102-105]  
Proteins that are introduced from one species of animal into another are often 
immunogenic in the recipient animal and lead to production of antibodies against the 
foreign protein. Introduction of a mouse protein into a goat, for example, will likely cause 
the goat to develop an IgM and then IgG response to the mouse protein. This anti-
species antibody production can be utilized by scientists to raise antibodies against 
human proteins for therapeutic use.  
Of note, amino acid sequences of antibodies also differ among species. This 
means that introduction of a mouse IgG into a goat could cause the goat to develop anti-
mouse IgG antibodies. Therefore, if scientists isolate an IgG with therapeutic potential 
from a mouse, it is possible that patients that receive that same IgG will develop an 
immune response against it, rendering it ineffective. 
To prevent this from happening, recombinant DNA techniques can be used to 
produce chimeric antibodies. Chimeric antibodies are made by grafting the Fv portion of 
the desired, non-human IgG onto the constant regions of a human IgG. Rituximab, 
described above, is a chimeric IgG specific for human CD20 protein on B cells that was 
originally raised in a mouse injected with human CD20 protein [106-108].  During the 
development of rituximab, the murine constant regions of the most therapeutically 
promising mouse anti-human CD20 monoclonal antibody was replaced with human 
constant regions, making rituximab less immunogenic to patients.  
So called humanized antibodies replace the non-human IgG constant regions 
and almost all of the Fv with human IgG sequence. The non-human CDRs, which 
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include several “framework” amino acids that play a necessary role in CDR-epitope 
binding, are left intact. The result is an even less immunogenic IgG. Fully human 
antibody sequences can either be directly isolated from humans or from mice genetically 
engineered to express human antibodies. 
Genetic engineering can also be used to make antibody constructs, non-naturally 
occurring antibody-like proteins that maintain the antigen specificity of an antibody with 
or without the associated Fc-mediated effector function. One example of an antibody 
construct is an immunoadhesin. Immunoadhesins are proteins that are translated in a 
single reading frame as opposed to multiple reading frames as is the case for a full-
length antibody. The immunoadhesin heavy and light chain sequences are connected by 
a linker peptide that allows the expressed protein to form the Y-shaped structure of an 
IgG. Immunoadhesins lack CH1, located on the lower portion of the prongs of the IgG, 
making the DNA sequence of an immunoadhesin shorter than that of a full-length IgG. 
Because the immunoadhesin maintains a normal stalk portion of the IgG Y-shape, it can 
still mediate FcR functions and has a half-life similar to full-length antibodies.  
Another antibody construct is the scFv. Here, the VH and VL of an antibody are 
also translated in a single reading frame, connected by a linker peptide of 10-25 amino 
acids. In vivo, these proteins form into an Fv-like structure which can bind to an epitope. 
scFvs do not have an Fc, therefore they cannot mediate Fc effector functions. Their half-
life in blood is also much shorter than that of full-length IgG. 
In fact, IgG has an unusually long half-life in blood, 10 to 18 days, compared to 
other Igs. IgA or IgM have a half-life of only 5 to 6 days. This longer IgG half-life is due to 
the recycling function of the neonatal Fc receptor (FcRn). FcRn was originally 
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discovered in placenta where it transports antibodies from the blood of a mother to her 
fetus. It is expressed on many other tissues in the body where it plays various roles. 
 In the circulatory system, FcRn is expressed on the apical surface of endothelial 
cells lining blood vessels. These endothelial cells constitutively pinocytose plasma, 
which contains IgG as well as other Igs and proteins. The endosomes resulting from this 
pinocytosis are acidified and traffic to lysosomes where protein contents are normally 
degraded. However, IgG escapes this fate. As endosomes are acidified, IgG binds to 
FcRn in the lumen of the endosome. The FcRn-IgG complexes are then sorted into 
recycling endosomes which transport the IgG back to the apical plasma membrane. 
After the recycling endosome fuses with the plasma membrane, IgG dissociates from 
FcRn at physiological pH. This recycling function of FcRn is what gives IgG a long half-
life in the blood. [109] 
Section References 
Male, D.K., Immunology. 8th ed.  2013, Elsevier/Saunders: United States, 472 pp.[110] 
Murphy, K.P., et al., Janeway's Immunobiology. 8th ed. 2012, New York: Garland 
Science. 868 pp. [111] 
 
AAV-mediated delivery of antibodies  
IgG antibodies are proteins coded by genes. The human IgG heavy and light 
chain DNA sequences are approximately 1345 base pairs (bp) and 645b bp long, 
respectively. An antibody gene sequence can easily fit into an AAV genome along with 
the requisite regulatory elements. Thus, AAV vectors can be used to deliver the gene for 
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a monoclonal antibody to patients so that the patients’ own cells will produce the 
therapeutic antibody in vivo. [112] 
Expression cassettes designed for whole antibody gene transfer by AAV vectors 
must be engineered to express both the heavy and the light chains of an antibody. This 
can be accomplished from the same expression cassette in several ways. One method 
is to place an internal ribosome entry site (IRES) between the heavy and light chain 
sequences in the expression construct. However, for successful expression of a whole 
antibody, it is necessary for the light and heavy chain proteins to be produced at a 1:1 
ratio. Greater expression of light chain over heavy chain, for example, can lead to 
intracellular toxicity as well as pathologic deposition of complexes formed by aggregation 
of light chain in various organs. As the sequence upstream of the IRES in the expression 
construct may be translated more efficiently, using an IRES may cause unequal 
production of heavy and light chains. [113] 
Instead, using a so-called 2A peptide motif between the light and heavy chain 
sequences allows for translation of the heavy and light chains together followed by a 
“self-cleavage” event during translation. 2A motifs are derived from viruses. For 
example, F2A was derived from foot-in-mouth virus. Self-cleavage of the 2A polypeptide 
occurs between a glycine and proline residue at the C terminus. The addition of a furin 
recognition sequence upstream of the 2A but downstream of the first gene allows 
removal of the 2A residues from the upstream gene by furin enzymatic cleavage. Using 
this technique, equal ratios of heavy and light chains are produced, increasing the 
efficiency and safety of antibody gene translation over the use of an IRES. [113]  
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 An alternative to expressing a whole antibody is expressing an antibody 
construct, many of which are transcribed in a single reading frame and form the correct 
conformation in vivo. These antibody constructs may include the immunoadhesin or 
scFv, described above. 
Using AAV vectors to deliver monoclonal antibodies to patients is not a novel 
concept. Balazs et al. and Johnson et al. pursued this technique to introduce antibodies 
to animal models for “vectored immunoprophylaxis” against HIV.  This may be 
conceptualized as an in vivo passive vaccination. Using the gene sequence of a broadly 
neutralizing antibody to the human immunodeficiency virus (HIV) as a transgene, AAV 
vectors were manufactured for intramuscular (IM) delivery. Muscle cells transduced by 
the vector would produce the anti-HIV antibody constitutively. The antibody would 
distribute into the circulatory system and throughout the body, thus conferring protection 
from HIV infection. [114, 115] 
In one report, HIV-susceptible humanized mice were injected intramuscularly 
(IM) with an AAV vector containing a broadly-neutralizing HIV antibody transgene. The 
full-length antibody was detected in mouse serum, and subsequent challenge with very 
high doses of replication-competent HIV yielded no successful infection. A later report 
described intramuscular administration in NHPs of 2e13 GC of an AAV vector with an 
anti-simian immunodeficiency virus (SIV) antibody transgene. Subsequent IV challenge 
with virulent SIV yielded no productive infection; all animals were completely protected. 
[114, 115]  Going forward, AAV delivery of antibodies thus shows promise for a variety of 
gene therapy applications. 
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CHAPTER 4 
Human epidermal growth factor receptor 2 (HER2) 
Human epidermal growth factor receptor 2 (HER2) is a 185 kDa membrane-
associated tyrosine kinase that is expressed on cells throughout the body. It is one of 
four members of the HER family of proteins which serve to transduce extracellular 
growth signals and thus regulate cell survival and differentiation.  HER2 has no known 
ligand, unlike other members of the HER family of proteins which bind such ligands as 
neuregulin (NRG) and extracellular growth factor (EGF, hence the more common name 
of the HER1 protein, extracellular growth factor receptor or EGFR). Rather, the native 
conformation of HER2 resembles that of other ligand-bound HER proteins. [116-124] 
HER2 signal transduction begins with heterodimerization of ligand-bound 
members of the HER family with HER2, the most potent combination of which is the 
HER2/HER3 heterodimer. In normal cells, HER2 may homodimerize relatively 
infrequently. These dimerization events lead to auto-phosphorylation and recruitment of 
intracellular adapter proteins at the plasma membrane. This, in turn, leads to activation 
of master regulators of cell growth and survival, including the phosphatidylinositol 3-
kinase/Akt (protein kinase B)/NFkB pathway and the mitogen-activated protein kinase 
(MAPK) pathway. HER2 signal transduction is also associated with organogenesis 
during fetal development and with tissue maintenance in adults. [116-124]  
Overexpression of HER2 due to gene amplification is oncogenic. Cancer cells 
that overexpress HER2 are termed HER2+ and may have up to 2- to over 20-fold more 
HER2 expression than normal cells [125, 126]. As such, HER2 homodimerization occurs 
more frequently in these cells, leading to greater ligand-independent growth signal 
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transduction. Several types of cancers may overexpress HER2 including breast, 
stomach, uterine, and ovarian.  
Breast cancers are of particular interest with respect to HER2 overexpression, as 
approximately 20% of these cancers are HER2+, portending more aggressive disease 
with a poorer prognosis than HER2- cancer.  Whether or not a tumor is deemed HER2+ 
is determined either by a tumor HER2 IHC status of 3+ or greater, a HER2 gene copy 
number of 6 or more by fluorescence in situ hybridization (FISH), or a HER2/CEP17 ratio 
of greater than 210 by FISH on chromosome 17. [117, 118, 120, 125-133]  
 
HER2 and trastuzumab (Herceptin®) 
 Trastuzumab was the first therapeutic monoclonal antibody to target HER2. It 
was developed by Genentech, and in 1998 it was approved for first-line treatment of 
metastatic HER2+ disease in combination with paclitaxel chemotherapy or as a second- 
or third-line agent by itself. In the 1980s, scientists at Genentech and the National 
Cancer Institute discovered that HER2 overexpression was linked to breast cancer and 
that cancers in which HER2 was overexpressed led to more aggressive disease, as 
described above. [134] Genentech then developed a series of monoclonal antibodies 
raised in mice against human HER2. One of these mouse anti-human HER2 IgGs, 
termed 4D5, bound to the extracellular domain IV of HER2 and was able to suppress the 
growth of HER2+human cancer cells both in vitro and in murine xenograft tumor models. 
[118, 119, 135, 136]  
To lessen the chance that 4D5 would induce an anti-mouse IgG immune 
response in patients, it was humanized as described above in “Antibodies” in Chapter 3. 
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Briefly, the antigen-binding portions of 4D5, including the CDRs, were inserted into the 
framework of a human IgG1. The resulting “humab4D5-8” antibody is what is known 
today as trastuzumab. Trastuzumab was found to bind to HER2+ cancer cells with a 
dissociation constant of 0.1 nM. [118, 137, 138]  
Trastuzumab has become part of the standard of care for patients with HER2+ 
primary and metastatic breast cancer. It is also approved for the treatment of HER2+ 
gastric cancer. Trastuzumab may be administered as adjuvant to chemotherapy, 
meaning it is administered along with chemotherapy after surgery or radiation to reduce 
the risk of recurrence or metastasis, or as neoadjuvant therapy, meaning as an agent 
that is used to shrink a tumor before surgical resection. It is usually given at a loading 
dose of 4 mg/kg body weight and at 2 mg/kg body weight for the duration of therapy. 
This regimen maintains the trastuzumab serum trough concentration at around 10-20 
µg/mL in serum. [127] 
Many clinical trials were initiated beginning in the 1990s to evaluate trastuzumab 
as an agent to treat HER2+ metastatic breast cancer, both as a single agent and along 
with chemotherapy. To evaluate the safety of trastuzumab and its pharmacokinetics, 
phase I clinical studies were conducted in patients with metastatic HER2+ breast cancer 
refractory to treatment. In one study, patients were dosed IV either a single time or 
weekly with 10-500 mg of trastuzumab along with cisplatin chemotherapy. No serious 
adverse events (SAEs) related to trastuzumab administration were reported. A maximum 
tolerated dose was not reached in this trial, and the half-life of trastuzumab in blood at 
the 500 mg dose was determined to be 2 weeks. [118, 139] 
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Phase II studies to evaluate the efficacy of trastuzumab were initiated with 
trastuzumab as a single agent in patients with metastatic HER2+ breast cancer. The first 
phase II trial involved 43 evaluable patients. The trastuzumab dose was 250 mg in the 
first week and 100 mg every week subsequently for 10 weeks. One patient in this study 
achieved a complete response to therapy for 6 years, and 4 patients achieved a partial 
response. The combination of complete responders and partial responders represents 
the overall response rate to treatment, in this study equal to 11.6%. 37% of the patients 
experienced a minimal response to treatment, and disease progressed in the remaining 
22 individuals. The median time to disease progression after initiation of therapy was 5.1 
months [118, 138, 140, 141] 
Another phase II study administered trastuzumab with cisplatin chemotherapy to 
39 patients with HER2+ metastatic breast cancers that were treated with previous 
chemotherapy but had relapsed. The dose of trastuzumab was the same as the single-
agent phase II trial above. There were 37 evaluable patients in this trial. Though none 
had a complete response, 9 patients experienced a partial response. 3 patients had a 
minor response. Disease stabilized in 6 patients and progressed in 19 patients. The 
overall response rate was thus calculated to be 24.3%. The median survival was 11 
months, and the median response duration was 5.3 months. [118, 138] 
The largest phase II trastuzumab clinical trial was an open-label, single-arm 
study conducted across 54 centers. 222 patients were included who had been treated 
with one or two previous cytotoxic chemotherapy regimens but in whom disease had 
relapsed. In this trial, trastuzumab dose was calculated based on body weight of the 
patients at a 4 mg/kg loading dose (first dose) and a 2 mg/kg maintenance dose 
(subsequent doses). Patients also received chemotherapy in the form of doxorubicin or 
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epirubicin plus cyclophosphamide or, if patients had already received anthracycline 
chemotherapy, paclitaxel. Of 204 evaluable patients, eight achieved a complete 
response and 26 achieved a partial response. The overall response rate was calculated 
to be 15%. 12 patients had a minimal response to trastuzumab treatment and 62 had 
stable disease. The rest of the patients experienced disease progression. The median 
duration of response to therapy was determined to be 9.1 months, and median survival 
was 13 months.  
Interestingly, patients whose disease showed greater HER2 overexpression by 
immunohistochemistry responded better to trastuzumab therapy in this trial. Average 
serum trastuzumab peak and trough concentrations among all patients were calculated 
to be 100.3 µg/mL and 25 µg/mL, respectively. Mean trough trastuzumab concentrations 
in patients with complete responses were higher at weeks 7 and 8 of therapy (70.3 
µg/mL) as opposed to serum trastuzumab concentration in patients with partial 
responses (54.8 µg/mL). The half-life of trastuzumab in this study was calculated to be 
6.2 days. [118, 138, 142] 
Following these phase I and II studies, phase III randomized, placebo-controlled, 
multi-center trials were conducted in over 900 women with HER2+ metastatic disease. In 
the pivotal phase III trial, 469 patients were included with a median follow-up time of 29 
months. These women had received prior chemotherapy. The trastuzumab dose was 4 
mg/kg in the first week followed by 2 mg/kg in subsequent weeks. More patients who 
received trastuzumab plus chemotherapy in this trial were still living one year after 
initiation of treatment (79%) compared to women who received chemotherapy only 
(68%). Patients who received trastuzumab also had a significantly longer median 
survival, 25.4 months compared to 20.3 months in patients who received chemotherapy 
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alone. The approximate increase in median survival was calculated to be 25%. Time to 
disease progression was longer in patients in the trastuzumab arm of the trial, 7.6 
months compared with 4.6 months in the chemotherapy arm. The overall response rate 
was higher in patients who received trastuzumab and chemotherapy, 49% compared to 
32% in patients who received chemotherapy alone. [143-145] 
Further phase III trials were conducted in over 3500 patients with operable, node 
positive HER2+ breast cancer. These studies compared treatment with 1 year of 
adjuvant trastuzumab plus chemotherapy (doxorubicin plus cyclophosphamide followed 
by paclitaxel) to chemotherapy alone. When analyzed together, the studies indicated 
that patients who received adjuvant trastuzumab in addition to chemotherapy 
experienced recurrence of their tumors at a 52% lower rate than patients who received 
chemotherapy alone. The risk of death after 24 months of follow-up was calculated to be 
33% lower in patients in the trastuzumab arm. [146] 
Even after metastatic HER2+ breast cancer progresses, trastuzumab treatment 
has been shown to extend median overall survival as demonstrated in five randomized 
clinical trials (114, 118-123). Additionally, a study of 247 patients who continued to 
receive trastuzumab after disease progression found it to be well-tolerated without 
increased incidence of adverse events such as cardiotoxicity (170). 
Following the approval of trastuzumab by the FDA in 1998, the repertoire of 
targeted treatments for HER2+ cancer has continued to expand. One of these drugs is a 
modified trastuzumab treatment called trastuzumab emtansine (Kadcyla). Kadcycla is 
trastuzumab conjugated to the cytotoxic agent emtansine (DM1), an inhibitor of 
microtubule assembly. Trastuzumab emtansine takes advantage of the ability of 
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trastuzumab to home to cells that overexpress HER2, allowing for localized, effectively 
concentrated delivery of emtansine to tumors.  
In clinical trials of Kadcyla, patients with locally advanced or metastatic breast 
cancer previously given trastuzumab and chemotherapy were included. A median 
survival was not reached in patients who received trastuzumab emtansine, but a median 
survival of 23.3 months was reported in patients that received a chemotherapeutic 
regimen of capecitabine and lapatinib (described below). The overall response rate in 
patients that received trastuzumab emtansine was 43.6% as opposed to 30.8% of 
patients who received chemotherapy. [147] 
Another HER2-targeted agent is the monoclonal antibody pertuzumab. 
Pertuzumab works synergistically with trastuzumab, binding to the extracellular domain 
of HER2 to disrupt HER2/HER3 dimerization. In patients with operable HER2+ breast 
cancer, adding pertuzumab to trastuzumab therapy increases the duration of disease-
free survival.[148]  
Finally, lapatinib is a small molecule inhibitor of HER1 and HER2, targeting the 
intracellular domain of these proteins. It is used to treat patients with metastatic HER2+ 
breast cancer and is discussed further in Chapter 6 “HER2+ breast cancer brain 
metastases.”  
The mechanisms of action of trastuzumab  
 Therapeutic monoclonal antibodies targeted against cancer may exert their 
effects in many different ways. The first FDA-approved monoclonal antibody developed 
against cancer, rituximab, was shown to work mainly by activation of the complement 
cascade, leading to tumor cell lysis. However, its other mechanisms of action have been 
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elucidated in the literature, including interruption of cell signaling and immune cell-
mediated cytotoxicity. [149]. The various methods by which trastuzumab exerts its anti-
tumor activity have also been extensively studied. 
 The main mechanism of action of trastuzumab is mediating a process called 
antibody-dependent cell-mediated cytotoxicity (ADCC). Trastuzumab bound to HER2 on 
a tumor cell is engaged by an NK cell possessing an activating FcR, such as FcγRIIIa. 
The activating FcR binds to the Fc portion of trastuzumab, inducing the NK cell to 
release cytotoxic proteins such as perforins, which form holes in the tumor cell 
membrane, and granzymes, proteases which activate apoptosis of the targeted cell, 
leading to tumor cell death. Other immune cells such as macrophages also possess 
activating Fc receptors and can undergo antibody-dependent cell-mediated 
phagocytosis (ADCP), a process by which the macrophage devours the trastuzumab-
decorated tumor cell. In vivo, NK cells are the main effector cells governing trastuzumab-
mediated cytoxicity.[150] 
 Several studies have demonstrated that trastuzumab mediates ADCC both in 
vitro and in vivo. In 2001, Clynes et al. reported failure of trastuzumab treatment to arrest 
growth of HER2+ xenografted tumors both in nude mice lacking activating FcRs and in 
mice treated with an antibody to disrupt Fc binding to FcRs. It was determined that an 
activating FcR is necessary for trastuzumab to exert an anti-tumor response. [151]  
Gennari et al. studied peripheral blood mononuclear cells (PBMCs) from breast 
cancer patients treated with trastuzumab as a single agent in the neoadjuvant setting, 
with surgical resection of tumor 7 days after trastuzumab administration. In vitro ADCC 
assays were performed using patient serum from before or after trastuzumab treatment 
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applied to HER2+ target cells. This was followed by application of autologous PBMCs. In 
most patients who had received trastuzumab therapy, there was significant killing of 
HER2+ target cells by autologous PBMCs. Interestingly, using PBMCs from patients with 
a better clinical response to trastuzumab therapy led to a higher degree of tumor cell 
death in vitro. Additionally, tumor samples from patients treated with trastuzumab were 
unable to be stained histologically by trastuzumab conjugated to horseradish peroxidase 
(HRP), suggesting that available antigen binding sites on the tumor cells were saturated 
by already-bound trastuzumab [152]. 
Arnould et al. used histology techniques to study immune cell infiltrates in tumor 
samples of patients also treated with trastuzumab in the neoadjuvant setting. 23 patients 
who received trastuzumab and docetaxel for 17 weeks underwent surgical resection of 
the primary tumor after the last cycle of combined trastuzumab and docetaxel treatment. 
Case-matched controls received docetaxel without trastuzumab. Pathologists analyzed 
tumor slides for the presence of B cells, T cells, macrophages, dendritic cells, and NK 
cells. Trastuzumab treatment resulted in an increase in the number of NK cells 
associated with the tumor and increased expression of granzymes and TiA1, a pro-
apoptotic protein, in tumor-infiltrating lymphocytes. [153] 
Trastuzumab has been shown to exert its anti-tumor effect by other mechanisms 
as well.  Trastuzumab blocks homodimerization of the HER2 protein, preventing signal 
transduction and leading to inhibition of pathways associated with cell survival. For 
example, when tumor cells are exposed to trastuzumab in vitro, MAPK and PI3K/AKT 
cell growth-associated pathways are downregulated.  [150, 154, 155]   
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Trastuzumab has also been shown to prevent cleavage of the extracellular 
domain of HER2 on tumor cells, which occurs normally and is mediated by 5-
aminophenymercuric acetate matrix metalloproteinase activator. The remaining p95 
membrane-associated protein is able to transduce growth signals by itself. [155-157]  
Trastuzumab has also been shown to inhibit tumor-associated angiogenesis. 
Tumors normally secrete vascular endothelial growth factor (VEGF), and increased 
VEGF expression is associated with HER2 overexpression. In a xenograft model, 
trastuzumab administration led to decreased tumor vascularization as well as 
normalization of tumor vascular permeability, diameter, and volume. VEGF mRNA 
expression was also decreased in trastuzumab-treated tumor cells in this experiment. 
[158]  
Finally, HER2 signaling is important for activating DNA repair pathways. Treating 
cancer cells with trastuzumab downregulates these DNA repair pathways. Studies by 
Pietras et al. in 1998 and 1999 in murine xenografts showed a 35-40% reduction of 
cisplatin-induced DNA damage in vivo after trastuzumab treatment as well as prevention 
of a slow S phase necessary for tumor cells to repair radiation-induced DNA damage 
[159, 160]. 
 
Trastuzumab-related cardiotoxicity  
A small number of patients who received trastuzumab in the pivotal phase III 
clinical trial described above developed cardiac dysfunction. Those who received 
concurrent anthracycline chemotherapy, such as doxorubicin (Adriamycin) were 
particularly affected. 27% of patients who received trastuzumab plus an anthracycline 
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developed systolic dysfunction compared with 8% of patients who received an 
anthracycline alone.  
At first, it was believed that the combination of trastuzumab and anthracyclines 
led to this cardiac dysfunction. However, endomyocardial biopsies of patients with 
trastuzumab-associated cardiotoxicity did not show the same ultrastructural changes 
known prior to be associated with anthracycline-associated cardiotoxicity. The dose of 
trastuzumab that a given patient received also did not correlate with the development of 
cardiotoxicity. Later studies conducted in patients without previously diagnosed 
cardiovascular disease who did not receive anthracyclines simultaneously with 
trastuzumab still reported cases of cardiotoxicity. In these reports, the risk of 
trastuzumab-associated heart failure was 3.9%. [116, 161-163] 
Although the exact mechanism of trastuzumab-induced cardiotoxicity is not fully 
understood, scientists have discovered that cardiomyocytes require some baseline level 
of HER2 signaling for normal function [161]. Mouse models were developed with 
conditional knock-outs of HER2 and HER4 in ventricular tissue. By 8-12 weeks of age, 
these mice had already developed dilated cardiomyopathy, and the cardiomyocytes of 
these mice were more susceptible to anthracycline-induced death. NRG, which binds to 
HER4, was found to play a large role in the recovery of cardiomyocytes after stress. 
HER2 signaling was also suggested to be involved in formation and maintenance of the 
conduction system of the heart, contractility, regulating myofilament architecture, 
glucose metabolism, and angiogenesis. [162, 164-168]  
 Extensive research has been performed to determine a patient’s risk for 
developing trastuzumab-associated cardiotoxicity. A 2012 meta-analysis of multiple 
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large clinical trials (11,911 women total) indicated that trastuzumab treatment was 
associated with an increased risk for severe heart failure (2.5 vs. 0.4%) and a reduction 
in left ventricular ejection fraction (LVEF), a measure of heart function. This 
trastuzumab-associated reduction in LVEF manifests asymptomatically in the majority of 
patients who experience it. [169]  
The National Adjuvant Breast and Bowel Project (NSABP) B31 7-year follow-up 
found that patients who received trastuzumab had a 4% 7-year cumulative risk of a 
cardiac event compared to a 1.3% cumulative risk for patients who did not receive 
trastuzumab. A cardiac event was defined as definite or probable cardiac death, heart 
failure (dyspnea with normal activity or at rest) with an LVEF decline of greater than 10% 
from baseline, or an LVEF of <55%. [170] 
The Herceptin Adjuvant Trial (HERA, BIG1-01) 8-year follow-up compared 
patients who received 2 years of trastuzumab (n=1673), 1 year of trastuzumab (n=1682), 
or observation (n=1744). Congestive heart failure was reported in 0.8%, 0.8%, and 0% 
of patients, respectively.  A significant LVEF decrease was reported in 7.2%, 4.1%, and 
0.9% of these patients, respectively. Severe congestive heart failure and cardiac death 
were found to be rare in all study arms. Of patients who experienced a significant 
decrease in LVEF, acute recovery was reached in 87.5% of patients who received 2 
years of trastuzumab treatment and 81.2% of patients who received 1 year of 
trastuzumab treatment. [171]  
Another phase III trial reported that 33 patients who developed a cardiac event 
(most often an asymptomatic decline in LVEF) continued trastuzumab treatment. 85% of 
these patients’ cardiac function eventually improved or remained the same. This study 
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also found that 75% of patients with symptomatic cardiotoxicity experienced reversal of 
symptoms when treated with standard heart failure therapy (including, but not limited to, 
angiotensin converting enzyme inhibitors, aldosterone antagonists, angiotensin receptor 
blockers, or beta blockers) [161].  
A retrospective review of 49 patients with trastuzumab cardiotoxicity drew similar 
conclusions. In this study, 79% of patients who experienced cardiotoxicity subsequently 
recovered with appropriate heart failure therapy and withdrawal of trastuzumab. Of these 
patients, 26 resumed trastuzumab treatment. Only 10 patients developed cardiac 
dysfunction again, and 5 of these patients continued to receive trastuzumab therapy, 
with a slight decrease in LVEF as the only indication of cardiotoxicity. [172] 
In another study, risk factors associated with trastuzumab cardiotoxicity were 
found to be patient age greater than 50 years, previous or concurrent use of 
anthracycline chemotherapy, preexisting cardiac dysfunction, and overweight (>30) body 
mass index. Antihypertensive therapy, diabetes, valvular heart disease, and coronary 
artery disease were not found to increase the risk of cardiotoxicity [173].  
Other HER2-targeted chemotherapies have also been reported to cause 
cardiotoxicity. Pertuzumab is another monoclonal antibody that targets a different 
epitope of HER2 than trastuzumab, and it is often co-administered with trastuzumab. In 
the CLEOPATRA trial, 8.3% of patients who received placebo, trastuzumab, and 
docetaxel experienced decreased LVEF compared with 4.4% who received pertuzumab, 
trastuzumab, and docetaxel. The cardiotoxicity of lapatinib has also been studied. A 
meta-analysis of 49 trials in (n=3689 patients total) concluded that 1.4% of patients who 
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received lapatinib experienced asymptomatic cardiac events and 0.2% of patients 
experienced congestive heart failure. [173] 
In summary, trastuzumab cardiotoxicity occurs in a small but significant 
percentage of patients treated with trastuzumab. The exact percentage varies depending 
on the study but ranges from less than 1% to about 10%. In the majority of these 
patients, cardiotoxicity manifests as an asymptomatic decline in LVEF, with many fewer 
developing fulminant heart failure. The occurrence of cardiotoxicity is not related to the 
dose of trastuzumab that patients receive. Instead, cardiotoxicity is more likely to occur if 
a patient received or is receiving anthracycline chemotherapy or if they have preexisting 
cardiac dysfunction such as a low baseline LVEF. Older and overweight individuals are 
also at higher risk for developing cardiotoxicity. Most patients who experience 
cardiotoxicity recover baseline cardiac function after trastuzumab is withdrawn and/or 
standard heart failure drugs are administered. A large subset of the patients who 
experience trastuzumab cardiotoxicity will resume trastuzumab treatment and 
experience no further cardiac episodes. The mechanism of cardiotoxicity is not fully 
understood, but it known that HER2 signaling is linked to cardiomyocyte survival. 
Importantly, studies have shown that long-term administration of trastuzumab is 
generally well-tolerated. 
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CHAPTER 5 
HER2+ breast cancer brain metastases (BCBM) 
Compared to other subtypes of breast cancer, HER2+ disease has the second 
poorest overall prognosis, tends to be more aggressive, and has a higher propensity to 
metastasize to other organs, including the brain [119, 125]. Brain metastases are a 
devastating sequela of HER2+ breast cancer, with reports indicating an incidence of 15-
35.2% among patients with HER2+ disease compared to 10-16% of patients with any 
type of breast cancer. [129, 174-193] Interestingly, autopsies of patients with any type of 
breast cancer and no clinical evidence of brain metastases have found that up to 30% of 
patients have pathologically evident metastases or micrometastases at death [161, 194-
196]. 80% of brain metastases are detected after the diagnosis of systemically 
metastatic disease. There is a 75% chance that if primary breast tumor is HER2+, brain 
metastases will also be HER2+. [127, 128, 197]. In most retrospective studies of patients 
presenting with breast cancer brain metastases (BCBM), CNS disease was discovered 
after clinical reports of headache or neurological deficits due to the mass effect of brain 
tumors. [194] 
Approximately 17,000 women every year will be diagnosed with HER2+ BCBM in 
the US, and the median survival of these patients will be 10-13 months from the time of 
diagnosis [174], although the RegistHER prospective observational study results 
published by Brufsky et al report a median survival of 17.5 months [198]. Other studies 
indicate that only 20% of HER2+ BCBM patients will be alive a year after diagnosis of 
CNS disease and that these patients these patients tend to be younger (less than 50 
years old) and have 2 or more metastatic foci outside of the CNS [198-200].  A reported 
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41-52% of patients die as a result of BCBM progression as opposed to other causes 
including progression of systemically metastatic disease. [174, 194, 198, 201-204]  
A small percentage of patients with HER2+ BCBM will present with 
leptomeningeal carcinomatosis (LC), a rare type of brain metastasis with that accounts 
for 5% of patients with HER2+ BCBM [181, 204, 205].  In LC, tumor cells cloak the brain, 
spreading along the leptomeninges, a term that refers to the pia and arachnoid mater, 
which are membranous coverings of the brain between which flows CSF. Patients with 
LC have an even poorer prognosis than those with focal metastases, with median overall 
survival ranging from 2 to 5.2 months from the time of LC diagnosis. Most patients 
survive less than a year from the time of LC diagnosis. [204-209] 
Current treatments for HER2+ BCBM do not confer substantial survival benefit. 
The presence of the BBB excludes many chemotherapeutics and biological therapies 
that are used successfully to treat systemically metastatic disease, including anti-HER2 
monoclonal antibodies such as trastuzumab. The standard of care for patients with 
HER2+ BCBM depends on the number of tumor foci or whether the patient has LC. 
Patients with one or a limited number of focal metastases will typically undergo 
neurosurgical resection of their tumor(s) along with systemically-administered 
chemotherapy and/or trastuzumab plus pertuzuamb, despite the poor penetration of 
these treatments into the CNS [198]. A response to single-agent IV trastuzumab therapy 
is only seen in 11-15% of patients with HER2+ BCBM [140, 210].   
If feasible, stereotaxic radiosurgery, a high-energy type of focused radiation 
therapy, may be used against HER2+ BCBM, particularly in patients with a limited 
number of metastases or for whom surgical resection is contraindicated. If stereotaxic 
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radiosurgery is not available or if surgical resection is impossible, patients with multiple 
metastases will undergo whole brain radiation therapy, which can improve survival and 
reduce the frequency of intracranial relapse from 80% to 50% [185]. However, whole 
brain radiation therapy can carry a set of side effects including decreased IQ, cognitive 
deficits, urinary incontinence, and dementia [211]. Neither radiation treatment nor 
chemotherapy improves prognosis for patients with leptomeningeal disease [186, 193, 
206]. All too often, patients with systemically metastatic HER2+ disease receiving 
therapies including intravenous trastuzumab therapy will experience regression in 
visceral disease in response to treatment while CNS disease simultaneously progresses. 
[211]  
Patients with HER2+ primary or systemically metastatic disease treated with 
trastuzumab are at higher risk for developing brain metastases. This was discovered as 
a result of post-hoc anslysis of clinical trials including the NSABP B-31 and HERA 
studies mentioned above. In these trials, CNS metastases were recorded more 
frequently in patients who received trastuzumab therapy as opposed to control 
treatments.  
A few factors have been postulated to account for the increased incidence in 
HER2+ BCBM over the past several decades among patients who have received 
trastuzumab to treat visceral disease. The increasing efficacy of chemotherapeutic 
regimens and anti-HER2 agents to treat systemically metastatic HER2+ breast cancer 
and the corresponding increase in overall survival for these patients may allow time for 
the outgrowth of brain metastases that in the past may have remained undetectable 
before death. Additionally, poor penetration of trastuzumab into the CNS due to its size 
and thus a lack of HER2 blockade in HER2+ tumor deposits that are unappreciable 
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clinically or by imaging modalities may contribute to the increasing incidence of HER2+ 
BCBM. [129, 174, 177, 186, 193, 194, 198, 212]  
For patients with HER2+ BCBM, the small molecule lapatinib offers some clinical 
benefit. Lapatinib is an inhibitor of HER1 and HER2, targeting the intracellular domain of 
these proteins. In the LANDSCAPE phase II trial, which included patients with HER2+ 
BCBM that were previously untreated, 65.9% of patients experienced a partial response 
to lapatinib plus capecitabine. However, one phase III trial, called CEREBEL, studied the 
effect of lapatanib on the incidence of CNS metastases in patients with HER2+ 
systemically metastatic disease who did not yet have CNS metastases. Patients were 
treated either with lapatinib plus capecitabine or trastuzumab plus capecitabine. The 
study did not find a significant difference between the two treatment regimens in terms of 
incidence of CNS disease, progression-free survival, or overall survival. Other phase III 
studies with lapatinib are ongoing as of October 2017. [213, 214] Additional small 
molecule inhibitors of HER2 which may cross the blood-brain barrier to target HER2+ 
brain metastases are in development [215]. 
 
Intrathecal trastuzumab as HER2+ BCBM treatment 
 When administered IV, trastuzumab penetrates poorly into the CNS. Pestalozzi 
et al. illustrated this point in 2000, describing weekly IV trastuzumab administration in a 
patient with LC. On week one, a loading dose of 240 mg was administered. The 
following week, 120 mg trastuzumab was administered, and the patient’s serum and 
CSF were collected for ELISA. The trastuzumab concentration was determined to be 
61.392 µg/mL in serum and 0.210 µg/mL in CSF. Another week later, another 120 mg 
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trastuzumab was administered again, and serum and CSF were collected for ELISA. 
Serum trastuzumab was measured to be 70.336 µg/mL and CSF trastuzumab to be 
0.212 µg/mL [216]. This phenomenon is not limited to humans. In a preclinical study in 
mice by Abukayyas et al., a radio-labeled human IgG1 antibody was administered 
intravenously. The resulting brain-to-blood ratio of IgG in was determined to be 0.7%. 
[217, 218] 
Because IV trastuzumab does not cross the BBB effectively, many clinicians 
have administered trastuzumab intrathecally to patients with HER2+ BCBM “off-label.” 
Table 1, found in Chapter 6, lists case reports of patients with HER2+ BCBM, either LC 
or intraparenchymal disease. The table includes trastuzumab dose, dose frequency, 
indicated concurrent treatments, degree of clinical response, duration of response, 
adverse events (AEs) or serious adverse events (SAEs), and overall survival. For most 
of these patients, IT trastuzumab provides some clinical benefit. No AEs or SAEs have 
been reported related to IT trastuzumab administration.  
To examine the significance of the clinical benefit of IT trastuzumab, Zagouri et 
al. conducted a meta-analysis in 2013 of patients with LC who received IT trastuzumab 
treatment. The analysis concluded that overall survival increases from 5.9 months in 
historical controls to 13.5 months in patients who received IT trastuzumab. Additionally, 
68.8% of patients experienced significant clinical improvement. [219] 
 Two case reports have reported that IT trastuzumab can provide clinical benefit 
to patients with intraparenchymal disease. Bousquet and colleagues gave IT 
trastuzumab to a patient with HER2+ cerebellar and epidural breast cancer metastases, 
resulting in a six-month halt in disease progression [220]. Colozza and colleagues 
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describe a patient with HER2+ intraparenchymal cortical metastases who was treated for 
19 months with IT trastuzumab [221]. Both patients were still alive at the time of 
publication. 
 As a result of these successful reports, several clinical trials have been initiated 
to examine the effect of IT trastuzumab in patients with LC. Table 2 in Chapter 6 lists 
these ongoing trials, compiled from clinicaltrials.gov. Of note, IT trastuzumab is dosed in 
these trials within the range of 30-150 mg per administration. Interestingly, trastuzumab 
is not the only monoclonal antibody to show promise after IT administration for CNS 
malignancy. Rituximab administered IT has been tested in two phase I clinical trials and 
has shown benefit for patients with CNS B cell lymphoma [222, 223]. The anti-epidermal 
growth factor receptor (EGFR) antibody panitumumab has also administered to single a 
patient with EGFR mutant lung adenocarcinoma that metastasized to the brain [224]. 
 Although IT trastuzumab has shown promise, it is likely that the normal, rapid 
clearance of CSF compromises the efficacy of IT trastuzumab. In a study by Braen et al., 
cynomolgus macaques were given 3mg or 15mg trastuzumab by intrathecal infusion, 
with 3 macaques in each dose group. The mean concentration of trastuzumab in CSF in 
the 3 mg dose cohort one day after trastuzumab infusion was around 10,000 ng/mL.  
One week after infusion, the trastuzumab concentration in CSF was around 50 ng/mL. In 
the 15 mg dose cohort, the mean concentration of trastuzumab in CSF one day after 
infusion was around 20,000 ng/mL, and one week after infusion, the trastuzumab  
concentration was around 200 ng/mL [225].   
In the report by Bousquet et al where IT trastuzumab was administered to a 
patient with HER2+ cerebellar and epidural BCBM, the half-life of trastuzumab in CSF 
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was calculated to be around 12 hours. The half-life of trastuzumab in blood has been 
calculated by multiple studies. These include a trastuzumab half-life of 8.3 days after a 
100 mg IV dose in 45 patients [140], 28.5 days after a 2 mg/kg IV dose in 476 patients 
[226], and 6 mg/kg after the 12th IV dose in 15 patients [227]. Of note, the clinical trial 
conducted by Gutierrez et al. listed in Table 2 aims to achieve a CSF trastuzumab 
concentration of 30 µg/mL to maximize potential therapeutic effect.  
In summary, HER2+ BCBM are a devastating diagnosis that leave patients with 
few options for treatment. IT administration of trastuzumab has shown promise in 
several case reports, and clinical trials are being conducted to evaluate its efficacy in an 
official setting. Still, it is possible that combining an intrathecal trastuzumab treatment 
approach with AAV gene therapy techniques may improve survival for patients with 
HER2+ BCBM. It is also conceivable that an IT AAV gene therapy to express 
trastuzumab behind the BBB may serve as prophylaxis for patients with systemically 
metastatic HER2+ disease at risk for developing CNS disease. 
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CHAPTER 6                                                                                                       
Intrathecal AAV9.trastuzumab tumor prophylaxis and treatment in a murine 
xenograft model of HER2+ breast cancer brain metastases  
Introduction 
Breast cancer is the most commonly diagnosed malignancy in women in the US 
with an estimated 252,710 new cases in 2017 [228]. Approximately 20% of breast 
cancers overexpress HER2 and are considered to be more aggressive and more likely 
to metastasize to the brain than other breast cancer subtypes [175, 191, 229]. About 
30% of patients with metastatic HER2+ breast cancer will develop BCBM [174, 178, 193, 
230]. The registHER prospective study of patients with newly-diagnosed HER2+ 
metastatic breast cancer found that 37.3% of the 1012 patients studied developed brain 
metastases within 10.8 months from the initial diagnosis of metastatic disease [198]. 
Brain metastases can significantly lower patient quality of life by inducing nausea, 
sensory loss, aphasia, motor deficits, ataxia, seizures, stroke, and paralysis [175, 231-
233]. The median age at diagnosis of HER2+ BCBM is 48 years [234], and the incidence 
of HER2+ BCBM is rising [191]. It has been suggested that this increase is due to many 
factors. Targeted, effective therapies for HER2+ tumors in the periphery have increased 
the duration of patient survival, thereby allowing adequate time for outgrowth of brain 
metastases that would have otherwise remained subclinical before death [231, 235]. 
Many of these therapies, including biological therapeutics, do not reach adequate 
concentrations in cerebrospinal fluid (CSF) after systemic administration [216, 236].  
Current standard of care treatments for HER2+ BCBM are invasive, can cause 
cognitive impairment, and provide suboptimal survival benefit. Patients often undergo a 
combination of neurosurgical tumor resection, stereotaxic radiosurgery, whole brain 
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radiation therapy, systemic and/or intrathecal chemotherapy, steroids, or anti-HER2 
agents [175, 231, 235]. Even with these treatments, survival from the time of diagnosis 
of HER2+ BCBM ranges from 3 to 25 months with a median of 10-13 months [174, 188, 
198, 237]. Clearly, there is an unmet need for more effective, targeted treatments for 
patients with HER2+ BCBM. 
Trastuzumab (Herceptin®, Roche) is a humanized monoclonal antibody (mAb) 
directed against HER2 that extends survival of patients when used with chemotherapy to 
treat primary and systemically metastatic HER2+ disease [174, 210, 238]. However, 
trastuzumab does not cross the intact blood-brain barrier to treat central nervous system 
(CNS) tumors [175, 229]. Additionally, the CSF concentration of trastuzumab after 
intravenous (IV) administration is 300 to 400-fold lower than in serum [216, 236]. As 
such, patients with concurrent HER2+ BCBM and systemic HER2+ disease who receive 
IV trastuzumab often experience regression or stabilization of systemic tumor burden 
while brain metastases progress [174].  
Trastuzumab administered IT has been reported to increase survival and delay 
progression of HER2+ brain metastases. Bousquet and colleagues gave IT trastuzumab 
to a patient with HER2+ cerebellar and epidural breast cancer metastases, resulting in a 
six-month halt in disease progression [220]. Colozza and colleagues describe a patient 
with HER2+ intraparenchymal cortical metastases who was treated for 19 months with IT 
trastuzumab [221]. In both case reports, patients were still alive at the time of 
publication. A 2013 meta-analysis by Zagouri and colleagues demonstrated that the 
median survival of patients with HER2+ leptomeningeal carcinomatosis (LC), a 
particularly deadly form of BCBM, increases from 5.9 months in historical controls to 
13.5 months with IT trastuzumab treatment [219].  
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Despite these promising reports, IT administration of trastuzumab has 
disadvantages. Multiple intrathecal administrations are required. Perhaps more 
importantly, the normal, rapid turnover of cerebrospinal fluid (CSF) results in a widely-
fluctuating pharmacokinetic profile of trastuzumab in CSF, resulting in a CSF half-life of 
just 12 hours in one case report [220, 239]. It is therefore unlikely that tumor cells in the 
CNS receive optimal exposure to trastuzumab after IT administration. 
Gene therapy offers the potential for a one-shot solution to the problem of mAb 
delivery across the blood-brain barrier. Adeno-associated viral (AAV) vectors, 
particularly serotype 9, can safely and efficiently deliver exogenous genes, such as the 
gene for trastuzumab, to neurons and astrocytes throughout the brain and spinal cord 
after a single IT administration. This results in long-term, stable expression of the 
transgene product in the brain parenchyma and CSF [49, 56]. 
We aim to use AAV9.trastuzumab delivered IT to bypass the blood-brain barrier 
for localized expression of trastuzumab in situ. Using a Rag1-/- murine orthotopic 
xenograft model of HER2+ BCBM, we delivered AAV9.trastuzumab IT by 
intracranioventricular (ICV) injection either as tumor prophylaxis or as tumor treatment. 
In both cases, a single dose of IT AAV9.trastuzumab significantly extended median 
survival of mice compared to no treatment or control AAV vector treatment.  Looking 
ahead, we predict that IT AAV9.trastuzumab could prolong survival of patients with 
existing HER2+ CNS metastases in addition to patients with primary or metastatic 
HER2+ breast cancer at risk for developing BCBM. 
Hypotheses 
Using an orthotopic murine xenograft model of human HER2+ BCBM, we aimed 
to express trastuzumab in the CNS by administering AAV9.trastuzumab IT by way of 
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ICV injection. Vector was administered as tumor prophylaxis 21 days before tumor 
implantation or as tumor treatment 3 days after tumor implantation. In both the 
prophylactic and treatment setting, we expected mice that received AAV9.trastuzumab 
to survive longer than mice that received an AAV9 vector to express an irrelevant 
antibody or mice that received no treatment. 
The main mechanism of action by which trastuzumab exerts its anti-tumor effect 
in vivo is by mediating ADCC of tumor cells, chiefly by NK cells. We sought to 
demonstrate that this primary mechanism of action was preserved in our model and in 
the CNS compartment. When an NK cell depleting agent was administered systemically, 
we expected the median survival of mice that received AAV9.trastuzumab tumor 
prophylaxis to decrease compared to mice that received AAV9.trastuzumab tumor 
prophylaxis without the NK cell depleting agent.  Given that macrophages may perform 
ADCP on tumor cells, we also hypothesized that depleting macrophages in the systemic 
compartment of mice that received AAV9.trastuzumab tumor prophylaxis would lead to a 
shorter median survival than mice given AAV9.trastuzumab tumor prophylaxis without 
macrophage depletion. 
Results  
IT AAV9.trastuzumab provides tumor prophylaxis and treatment in a xenograft model of 
HER2+ BCBM 
We first tested AAV9.trastuzumab as HER2+ CNS tumor prophylaxis in our 
Rag1-/- xenograft model. No treatment, AAV9.trastuzumab, or AAV9.2.10AmAb (a 
negative control vector expressing a rhesus anti-simian/human immunodeficiency virus 
IgG) were administered IT by ICV injection at least 21 days before tumor implantation. 
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HER2+ BT474-M1.ffluc cells (100,000) were implanted in the brain parenchyma 
stereotaxically, and mice were monitored daily until moribund. Kaplan-Meyer survival 
curves (Fig. 1A-B) indicate that the median survival of mice that received IT 
AAV9.trastuzumab tumor prophylaxis was significantly greater than mice that received 
AAV9.2.10AmAb (124 days vs 46.5 days; p<0.0001, hazard ratio = 0.0306). The median 
survival of mice that received AAV9.2.10AmAb was not significantly different from mice 
without treatment (46.5 days vs 50 days; p=0.4306, hazard ratio = 1.1868). Protein A 
ELISA quantification of IgG transgene expression in serum (Fig. 1C-D) and brain tissue 
homogenate,  normalized to total protein in brain homogenate (Fig. 1E), indicates that 
transgene expression was similar between groups that received AAV9.trastuzumab and 
AAV9.2.10AmAb. Tumors remained HER2+ at the time of necropsy (Fig. 1F). 
Biodistribution analysis of AAV9 vector genome copies in brain tissue demonstrates 
equivalent genome deposition between groups that received vector (Fig. S1).  
To determine if IT AAV9.trastuzumab can serve as treatment for existing HER2+ 
BCBM, we implanted HER2+ BT474-M1.ffluc tumors in Rag1-/- mice and administered 
IT AAV9.trastuzumab or no treatment three days after tumor implantation. Kaplan-Meyer 
survival curves (Fig. 2) indicate that the median survival of mice that received 
AAV9.trastuzumab (82 days, p=0.002) is significantly greater than mice that received no 
treatment (61 days). 
To compare the amount of trastuzumab in brain tissue after ICV administration of 
AAV9.trastuzumab versus Herceptin®, 1e11 GC AAV9.trastuzumab or 15 µg 
Herceptin® were administered ICV to Rag1-/- mice. Assuming a mouse brain mass of 
0.4g, the 15 µg trastuzumab dose is equivalent to 37.5 µg trastuzumab/g brain mass.  
This dose would be the equivalent of a 50.625 mg dose of trastuzumab in a 1350 g 
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human brain. Brains from mice that received AAV9.trastuzumab were harvested 2 
weeks after vector administration, while brains that received Herceptin® were harvested 
24, 48, and 168 hours after antibody administration. Fig. S2 indicates that the median 
amount of trastuzumab expressed in brains tissue in mice that received 
AAV9.trastuzumab is slightly higher than the amount of Herceptin® in brain tissue 24 
hours after administration of 15 µg antibody. Over time, the amount of Herceptin® in 
brain tissue decreases, as expected.  
 
Prophylactic IT AAV9.trastuzumab slows tumor growth  
To determine if IT AAV9.trastuzumab tumor prophylaxis slows tumor growth, we 
measured tumor diameter 47 days after implantation. The median diameter of tumors 
from mice that received AAV9.trastuzumab tumor prophylaxis (1.2 mm, n=5) was 
significantly smaller than mice that received AAV9.2.10AmAb (5.7 mm, n=5) or no 
treatment (7.2 mm, n=4) (Fig. 3A). Transgene expression in brain tissue and in serum 
collected before tumor implantation shows higher but comparable median 2.10A mAb 
expression (Fig. 3B-C). 
 
Secreted trastuzumab binds to HER2+ brain tumors 
Anti-IgG immunofluorescence of day 47 tumor cryosections was employed to 
determine if secreted trastuzumab could bind to HER2+ tumor cells in vivo. Micrographs 
show trastuzumab decorating tumors from mice that received IT AAV9.trastuzumab but 
not tumors from mice that received IT AAV9.2.10AmAb or no treatment (Fig. 3D, 
overexposures Fig. S3A). Additionally, neurons transduced by AAV9.trastuzumab or 
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AAV9.2.10AmAb stain positive for IgG.  Secreted trastuzumab also decorated day 20 
tumors from mice that received AAV9.trastuzumab (Fig. S3B). Tumors remain HER2+ 
on the day of necropsy (Fig. S5). 
 
NK cells, but not macrophages, mediate IT AAV9.trastuzumab tumor prophylaxis 
Trastuzumab exerts its effect against peripheral tumors mainly by facilitating 
antibody-dependent cell-mediated cytotoxicity (ADCC) of HER2+ tumor cells [120, 151, 
240]. We hypothesized that the same mechanism would govern AAV9.trastuzumab 
tumor prophylaxis in the CNS. We first evaluated AAV9.trastuzumab tumor prophylaxis 
in NOD scid gamma (NSG) mice, which lack NK cells and functional macrophages. As 
expected, AAV9.trastuzumab tumor prophylaxis fails in NSG mice (Fig. 4). Survival was 
comparable between groups that received no treatment (37 days) or AAV9.trastuzumab 
(40 days, p=0.862). Transgene expression in brain tissue was similar among mice that 
received vector (Fig. S4). 
We next sought to determine if NK cells or macrophages played a larger role in 
IT AAV9.trastuzumab tumor prophylaxis in the CNS. To do so, we first employed 
continuous NK cell depletion by intraperitoneal (IP) administration of the anti-NK1.1 
antibody PK136 in our Rag1-/- xenograft tumor model (Fig. 5A-B). Mice that received 
AAV9.2.10AmAb with or without NK cell depletion survived a median of 53 and 50 days, 
respectively. Mice that received AAV9.trastuzumab tumor prophylaxis and no NK cell 
depletion lived a median of 156 days. Median survival of mice that received 
AAV9.trastuzumab tumor prophylaxis with continuous NK cell depletion was significantly 
shorter, 73 days (p<0.0001, compared to AAV9.trastuzumab without NK cell depletion). 
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Formalin-fixed tumors from mice in the NK cell depletion experiment were 
subjected to in situ hybridization (ISH) for NK cell-specific Ncr1 (NKp46) RNA. NK cells 
infiltrated only tumors from mice given AAV9.trastuzumab without NK cell depletion (Fig. 
5C). IgG transgene expression in brain tissue homogenate was comparable between 
groups that received vector (Fig. 5D). Ncr1 ISH of spleens was used to confirm 
successful depletion of NK cells (Fig. 5E). We also cryosectioned day 20 tumors from 
mice given AAV9.trastuzumab, AAV9.2.10AmAb, or no treatment without NK cell 
depletion. Immunohistochemical (IHC) staining for Ly-49G2 (Fig. 6) confirms that NK 
cells infiltrated day 20 tumors only from mice that received AAV9.trastuzumab tumor 
prophylaxis. 
 To determine if systemically-circulating macrophages play any role in 
AAV9.trastuzumab tumor prophylaxis in our model, we employed continuous 
macrophage depletion by IP administration of clodronate liposomes. Mice that received 
no treatment with or without macrophage depletion survived a median of 53 and 50 
days, respectively (Fig. 7A-B). Mice that received AAV9.trastuzumab without 
macrophage depletion survived a median of 92 days (p=<0.0001 compared to mice that 
received no treatment without macrophage depletion). Mice that received 
AAV9.trastuzumab with macrophage depletion survived a median of 70.5 days 
(p=0.3268, compared to AAV9.trastuzumab without macrophage depletion). IgG 
transgene expression in brain tissue was comparable among groups that received vector 
(Fig. 7C), and macrophage depletion was confirmed by IHC staining of spleens for CD68 
(Fig. 7D). 
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Discussion and further directions  
Metastasis of HER2+ breast cancer to the brain is a devastating diagnosis with a 
poor prognosis due to a lack of targeted and effective treatments. Although IT 
administration of trastuzumab has been reported to slow disease progression and 
prolong survival, the benefit is modest, likely due to the rapid turnover of CSF resulting in 
poor tumor exposure to antibody. An unmet need for effective treatments exists for 
patients with this disease.  
The advent of AAV vectors for gene transfer has revolutionized the field of gene 
therapy. The discovery of CNS-tropic vectors, such as AAV9, represents a boon for 
clinicians seeking to localize biological treatments behind the blood-brain barrier. A 
single IT administration of AAV9 vector into the CSF by way of the lateral ventricles or 
cisterna magna leads to widespread transduction of neurons and astrocytes throughout 
the cortex, cerebellum, and spinal cord, resulting in long-lived production of transgene 
product in the CNS compartment [14, 49, 56]. 
We have successfully demonstrated that AAV9.trastuzumab administered IT at a 
moderate vector dose, both as tumor prophylaxis and as tumor treatment, significantly 
extends median survival in a xenograft mouse model where the human HER2+ cancer 
cell line BT747-M1.ffluc is implanted into the brains of Rag1-/- mice. In the prophylactic 
setting, median survival is 2.48 times greater for mice that received AAV9.trastuzumab 
tumor prophylaxis than mice that received control AAV vector treatment or no treatment. 
Additionally, tumors in mice given AAV9.trastuzumab are smaller at day 47 than tumors 
from untreated or AAV9.2.10AmAb-treated mice. In the treatment setting, the median 
survival benefit is significant but less, perhaps in part due to the shorter total duration of 
exposure of tumor cells to expressed trastuzumab. Additionally, we report that a dose of 
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1e11 GC AAV9.trastuzumab administered ICV yields a similar amount of trastuzumab in 
brain tissue as does an ICV dose of Herceptin® equivalent to 50 mg in humans when 
measured 24 hours after antibody administration.  
Our studies also indicate that trastuzumab secreted by neurons and astrocytes 
maintains its antigen specificity and effector function despite the fact that these cells do 
not normally produce IgG. Using immunofluorescence microscopy, we showed that 
HER2+ tumors from mice treated with AAV9.trastuzumab, but not AAV9.2.10AmAb, are 
decorated with expressed IgG.  
The effector functions of trastuzumab have been widely studied [120, 240]. 
Trastuzumab bound to HER2 on tumor cells (i) mediates ADCC when its Fc binds to 
activating Fcγ receptors (e.g. FcγRIIIa) on immune cells such as NK cells and 
macrophages; (ii) prevents initiation of signal transduction when HER2 homodimerizes 
or heterodimerizes with other members of the HER family, thus slowing tumor growth; 
(iii) blocks proteolytic cleavage of the HER2 ectodomain preventing the remaining 
membrane-bound p96 protein from activating pro-growth signaling pathways; (iv) 
disrupts pro-angiogenic pathways; and (v) disrupts DNA repair pathways.  
The predominant mechanism by which trastuzumab acts against peripheral 
HER2+ tumors in patients is ADCC by immune cells carrying activating Fcγ receptors, 
such as NK cells and macrophages. We hypothesized that the same would be the case 
in our xenograft model. It is important to note that the mouse FcγRs do indeed bind to 
human IgG1. Overdijk et al. demonstrate that mouse FcγRs bind to human IgG1 and 
activate ADCC, and Bruhns reports that all human IgG subclasses are bound efficiently 
by mouse FcgRs and FcRn [241, 242].  
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AAV9.trastuzumab tumor prophylaxis fails when administered to NSG mice, 
which lack NK cells and functional macrophages compared to Rag1-/- mice, suggesting 
an NK cell- or macrophage-mediated mechanism of tumor prophylaxis. When we 
depleted NK cells in the Rag1-/- model, the median survival of mice decreased 
substantially, indicating that NK cell-driven ADCC of tumor cells is responsible for a 
majority of the survival benefit. Additionally, immunofluorescence and 
immunohistochemical staining of NK cells in tumors indicates that NK cells infiltrated 
only into tumors of mice that received AAV9.trastuzumab tumor prophylaxis, not 
untreated or control-treated mice. These NK cells are present in tumors as early as 20 
days after tumor implantation and as late as the time of necropsy. To our knowledge, 
this is the first time that the predominant mechanism by which trastuzumab works 
against HER2+ tumors in the CNS has been reported. 
Our macrophage depletion studies indicate that these cells do not contribute 
significantly to the anti-tumor effect of AAV9.trastuzumab tumor prophylaxis in this 
model. However, as clodronate liposomes do not cross the blood-brain barrier, these 
experiments can only address whether systemically-circulating macrophages play a role 
in AAV9.trastuzumab tumor prophylaxis. Tissue resident macrophages/microglia may 
still contribute in small part to the anti-tumor effect of AAV9.trastuzumab in this model. 
Limitations of our studies include our use of a single vector dose, although 
studies to determine a minimally effective dose (MED) are in progress. Our mice bore 
one brain tumor, but patients often develop multiple metastases. Testing 
AAV9.trastuzumab tumor prophylaxis in a model where tumor cells are administered via 
carotid artery injection or where brain metastases arise after implantation of a peripheral 
tumor would indicate whether our treatment is effective against multiple brain tumors. 
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We also employed AAV9.trastuzumab in these studies as a monotherapy. 
Unsurprisingly, all mice eventually succumb to outgrowth of tumors, which remain 
HER2+ at necropsy. Combining AAV.trastuzumab with chemotherapy and/or 
radiotherapy will likely be synergistic against HER2+ BCBM, both in this xenograft model 
and in patients.  
Trastuzumab infusion is standard of care for patients with HER2-overexpressing 
breast cancer, and IT delivery of trastuzumab has been shown to be beneficial. 
However, trastuzumab expression cannot be turned off after AAV9-mediated gene 
transfer. Related to this, cardiotoxicity is a known side-effect that occurs in a small 
subset of patients who receive systemic trastuzumab treatment. Risk factors for 
cardiotoxicity have been identified, including previous anthracycline-containing 
chemotherapeutic regimens, age, and existing cardiac dysfunction [243-245].  
With IT administration of IT AAV9.trastuzumab, we anticipate a lower 
concentration of trastuzumab in blood than after IV administration of Herceptin®, which 
would be less likely to lead to cardiotoxicity. Regardless, women with CNS metastasis 
from HER2+ breast cancer almost always have systemic disease necessitating 
treatment with systemic administration of trastuzumab where safety monitoring of 
cardiac function is standard. This aspect will be incorporated into the design of our first 
in human phase I safety trial.   
We plan to first assess the safety, efficacy, and pharmacokinetics of 
AAV9.trastuzumab in women with documented CNS lesions from HER2+ breast cancer. 
Subject to safety and efficacy in this setting, AAV9.trastuzumab will be subsequently 
assessed in a similar patient population with systemically metastatic HER2+ disease 
prior to clinical or radiological diagnosis of CNS lesions. Given that AAV transgene 
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expression has been documented to persist for years in non-human primates and 
humans [246, 247], this approach has the potential to be an integral part of the adjuvant 
therapy for patients with early diagnosis of HER2+ breast cancer after curative resection 
of the breast lesion.  
Given this fact and the results of our experiments, we intend to move 
AAV9.trastuzumab toward the clinic. Going forward, our AAV platform has the potential 
to be expanded to express other therapeutic antibodies behind the blood brain barrier to 
treat CNS diseases and address other unmet needs. 
 
Materials and Methods 
Experimental design 
IT-administered trastuzumab can increase survival and delay tumor progression 
in patients with HER2+ BCBM. However, trastuzumab has been reported to have a half-
life in CSF of 12 hours [220]. We aim to administer AAV9.trastuzumab IT such that 
trastuzumab can be constitutively secreted by neurons and astrocytes in situ leading to 
better tumor exposure to trastuzumab and thus longer median survival. To test our 
hypothesis, we chose Rag1-/- mice due to their lack of endogenous IgG and T cell 
“leakiness” that can occur in nude mice often used for HER2+ brain tumor xenografts in 
the literature. Both Rag1-/- and NSG mice used in these experiments were obtained 
from The Jackson Laboratory (Bar Harbor, ME, USA), housed at the barrier facility of the 
Translational Research Laboratories (TRL) Vivarium at the University of Pennsylvania, 
and maintained according to NIH guidelines for the care and use of animals in research. 
All procedures and protocols were approved by the Institutional Animal Care and Use 
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Committee (IACUC) of the University of Pennsylvania. The 2.10A mAb control antibody 
is a rhesus anti-simian/human immunodeficiency virus (SHIV) IgG, and the 
AAV9.2.10AmAb expression construct has the same regulatory elements as 
AAV9.trastuzumab. We administered vector to mice at least 21 days before tumor 
implantation in the prophylaxis studies and 3 days after tumor implantation in the 
treatment studies, because at least 10-14 days are required for vector expression to 
reach steady state. Sample size was determined to be a minimum of 8 mice per 
experimental group to allow for robust statistical analysis if mice were euthanized due to 
complications during or post-tumor implantation. The large prophylaxis study began with 
20 mice per group, the treatment study with 8 mice per group, and the NSG and NK cell 
depletion studies with 12 mice per group. Macrophage depletion studies began with 9 
mice per group, with an additional 2 mice added to AAV9.trastuzumab-treated arms due 
to clodronate-related toxicity. Mice found dead rather than euthanized were included 
only in the survival analyses and not in downstream transgene expression, histological, 
or biodistribution analysis. Studies were conducted without blinding.  
 
Statistics 
Survival study p values were calculated using the Log-Rank (Mantel-Cox) test in 
GraphPad Prism for Windows version 7 (GraphPad Software). Hazard ratios were 
calculated with a Cox regression model using the sts package in Stata (StataCorp). 
Tumor diameter comparisons were carried out using Wilcoxon rank-sum test within the 
R program (version 3.3.1; https//cran.r-project.org) using the function “wilcox.test.”  
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Vector construction 
Sequences matching the WHO published amino acid sequences of the heavy 
and light chains of trastuzumab were back-translated, codon-optimized, and synthesized 
by GeneArt (Life Technologies). Heavy and light chain sequences were preceded by a 
human IL-2 secretion signal. The heavy and light chain sequences were cloned into an 
AAV expression construct containing an upstream hybrid CMV immediate early 
enhancer/chicken beta-actin promoter and a Promega chimeric intron and a downstream 
SV40 polyadenylation signal. The heavy and light chain sequences were separated from 
each other by an F2A self-cleaving peptide to ensure 1:1 production of heavy and light 
chain protein. The construct was flanked by AAV2 inverted terminal repeats. The 
resulting pAAV.CMV.PI.trastuzumab.SV40 expression construct was packaged in an 
AAV9 capsid by triple transfection of 293 cells and purified as previously described [24]. 
Vector was titrated using standard qPCR. AAV9.CMV.PI.2.10AmAb.SV40 was obtained 
from the Penn Vector Core. 
 
Vector administration 
Six to nine-week-old female Rag1-/- (B6.129S7-Rag1tm1Mom/J) mice were 
obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and housed at the TRL 
Vivarium at the University of Pennsylvania. All animal procedures and protocols were 
approved by the IACUC of the University of Pennsylvania. Vector was diluted in sterile 
PBS. For IT administration by ICV injection, vector was diluted to 1 x 1011 GC per 5 µL.  
For tumor prophylaxis, mice were injected ICV with 1 x 1011 GC of 
AAV9.CMV.PI.trastuzumab.SV40 or AAV9.CMV.PI.2.10AmAb.SV40 at least 21 days 
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prior to BT474-M1.ffluc tumor implantation. For tumor treatment, mice received BT474-
M1.ffluc tumors first, and vector was administered by ICV injection 3 days after tumor 
implantation. 
 
Orthotopic xenograft model of HER2+ breast cancer brain tumors in Rag1-/- and NSG 
mice 
The xenograft model was based on previous HER2+ BCBM models reported in 
the literature [248-252]. The HER2+ BT474.M1 human ductal carcinoma cell line, 
transduced with the lentiviral vector VSVG.HIV.SIN.cPPT.CMV.ffluciferase.WPRE (Penn 
Vector Core), was cryopreserved in liquid nitrogen. One week before tumor implantation, 
BT474-M1.ffluc cells at passage 56 were thawed, expanded in DMEM/F12 (Corning) 
with 10% FBS and 1% penicillin/streptomycin at 37°C and 5% CO2, and passaged three 
days before tumor cell implantation. On the day of tumor injection, cells were counted 
with a Countess II cytometer (Life Technologies), and suspended at 1x105 cells per 5 µL 
in 50%/50% (v/v) PBS/MatriGel® (Corning).  
For the injection procedure, mice were anesthetized with ketamine/xylazine. Fur 
on the scalp and neck was sheared. A time-release 17-β estradiol pellet (1.7 mg, 90-day 
release, Innovative Research of America) was implanted subcutaneously in the dorsum 
of the neck and re-administered every 90 days during the study. Mice were fixed in a 
stereotaxic apparatus. Exposed skin was cleansed with povidone iodine and 70% 
ethanol. A 1 cm anterior-posterior incision was made over the top of the skull. Bregma 
was identified. A pneumatic drill was positioned at bregma then moved 0.8 mm posterior 
and 2.2 mm left of bregma where a burr hole was drilled in the skull.  
72 
 
A 25 µL Hamilton syringe was loaded with 5 µL of cell suspension and positioned 
in a mechanical injector on the stereotaxic frame. After bringing the needle to 0.8 mm 
posterior and 2.2 mm left of bregma, the needle was moved 4.0 mm deep into brain 
parenchyma then lifted 1.0 mm to create a pocket into which to inject cells.  The needle 
was left in place for 5 minutes. The cell suspension was mechanically injected over 10 
minutes, and the needle was left in place another 5 minutes before being removed 
slowly. After suturing incisions, mice recovered on a 37°C heating pad and were given 
100 µL of 2 mg/kg enrofloxacin in PBS and 0.3 mg/kg buprenorphine in PBS 
subcutaneously.  
Firefly luciferase imaging of tumor growth was not conducted in these studies. 
Our previous attempts to do so resulted in many mice developing acute urinary and 
kidney complications including hydronephrosis, kidney and bladder stones, and gross 
hematuria in the days immediately following the imaging procedure, necessitating 
euthanasia of affected mice. 17β estradiol, released from the subcutaneous pellet, has 
been reported in the literature to cause renal and urinary pathology[253-255]. It is 
possible that some aspect of our model exacerbated underlying kidney or urinary 
pathology associated chronic exposure to 17  estradiol. 
Mice were monitored daily. When moribund, mice were euthanized by 
overexposure to CO2 followed by cervical dislocation. At necropsy, brains and tumor 
were either snap-frozen on dry ice and stored at -80°C for transgene expression and 
genome copy analysis, cryopreserved in OTC medium using liquid nitrogen, or 
preserved in formalin.  
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Tumor diameter 
Measurement of  day 47 tumor diameter was performed with digital Vernier 
calipers (Thermo-Fisher). Brains were harvested at necropsy and cut coronally through 
the visible tumor injection needle track. The diameter of the tumor in the anterior section 
was calculated as the geometric mean of two perpendicular diameter measurements. 
 
NK cell depletion 
PK136 (anti-mouse NK1.1) antibody was purified from PK136 hybridoma 
supernatant (ATCC® HB-191™) using the protein A purification kit (Sigma) and 
supplemented as needed with PK136 available commercially (Leinco Technologies). 
Mice were given 100 µg PK136 or PBS intraperitoneally on days 5 and 1 before tumor 
implantation, then weekly for the duration of the experiment. 
 
Systemic macrophage depletion 
Chlodronate liposomes or PBS liposomes (Nico van Rooijen, Vrije University 
Medical Center, Amsterdam, the Netherlands) were injected intraperitoneally at 10 µL 
per g body weight on days 5 and 1 before tumor implantation, then weekly for the 
duration of the experiment. 
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Preparation of serum  
Blood was collected by retro-orbital or sub-mandibular bleed into Z-Gel microtube 
serum separators (Sarstedt) and incubated at room temperature for 20 minutes. After 
centrifuging for 5 minutes at 5000 RPM in a tabletop microcentrifuge (accuSpin micro 
17, Thermo-Fisher), serum was stored at -80°C. 
 
Preparation of brain homogenate 
Brain homogenates were prepared by chipping frozen brain into tissue lysis 
buffer (25 mM Tris-HCl, 5 mM EDTA, 1% Triton-X, 150 mM NaCl, pH 7.6) containing 3 
times the normal concentration of cOmplete™ Protease Inhibitor Cocktail Tablets 
(Roche). Samples were homogenized with stainless-steal beads on a TissueLyzer II 
(Qiagen) at 30 Hz for 2 minutes, frozen at -80°C, thawed, then centrifuged at 17K x g for 
60 minutes at 4°C to remove myelin debris. BCA assay (Thermo-Fisher) was used to 
determine protein concentration of brain homogenates. 
 
Protein A ELISA  
Protein A ELISA was used to quantify trastuzumab and 2.10A mAb expression in 
serum and brain homogenates.  All steps were performed at room temperature unless 
otherwise stated.  Plates were washed with a BioTek 405TS microplate washer with 
PBS + 0.05% Tween-20.  Protein A (Sigma) was suspended in PBS and stored at -20°C. 
Costar® 96-well EasyWash™ ELISA assay plates (Corning) were coated with 5 µg/mL 
protein A in PBS overnight at 4°C then blocked with PBS + 0.5% bovine serum albumin 
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(Sigma). Samples were diluted in PBS and plated. Herceptin® (Roche) was used as a 
quantitative standard. For brain homogenate ELISAs, brain homogenate from 
untransduced mice was spiked into the standard curve wells at a dilution equal to that of 
samples on the plate. After washing, plates were incubated with AffiniPure polyclonal 
goat anti-human IgG-biotin (Jackson ImmunoResearch Labs) followed by streptavidin-
horseradish peroxidase (Abcam). Plates were developed with TMB substrate, stopped 
with 2N H2SO4, then read using a SpectraMax M3 (Molecular Devices) plate reader at 
450 nm. 
 
Biodistribution by qPCR 
AAV9 vector genome copies in brain were quantified using TaqMan qPCR 
(Thermo-Fisher). Briefly, frozen brain tissue was chipped into ALT Buffer (Qiagen) and 
homogenized with steel beads using a TissueLyzerII. Phenol:chloroform:isoamyl alcohol 
(25:24:1, Sigma) extraction and isopropanol precipitation was used to isolate tissue 
DNA. For TaqMan qPCR, primers and probe were designed against the SV40 
polyadenylation signal of the vector.  
 
Histology  
HER2 staining was performed on formalin-fixed paraffin-embedded tissue 
samples. Sections were deparaffinized through a xylene and ethanol series, boiled in a 
microwave for 6 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval, treated 
sequentially with 2% H2O2 (15 min; Sigma), avidin/biotin blocking reagents (15 min each; 
Vector Laboratories), and blocking buffer (1% donkey serum in PBS + 0.2% Triton for 10 
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min) followed by incubation with primary antibody (1 h, rabbit anti-HER2, Abcam 
ab2428) and biotinylated secondary antibody (45 min; biotinylated donkey anti-rabbit, 
Jackson Immunoresearch, West Grove, PA) diluted in blocking buffer. Bound antibodies 
were visualized with a Vectastain Elite ABC kit (Vector Laboratories) using DAB as 
substrate. Sections were counterstained with hematoxylin to show nuclei. 
Immunofluorescence staining for human IgG was performed on cryosections. 
Sections were fixed in 4% paraformaldehyde in PBS for 10 minutes, permeabilized and 
blocked in 0.2% Triton in PBS containing 1% donkey serum for 30 minutes, and 
incubated for 1 hour with a goat antibody against the crystalizable fragment (Fc) of 
human IgG (Jackson Immunoresearch Laboratories, West Grove, PA; 109-005-098) 
diluted in 1% donkey serum/PBS. After washing sections in PBS, bound primary 
antibodies were detected with FITC-labeled secondary donkey anti-goat antibodies 
(Jackson Immunoresearch Laboratories) diluted in 1% donkey serum/PBS. After 
washing in PBS, sections were mounted with Vectashield containing DAPI as nuclear 
counterstain. 
Immunohistochemistry to detect NK cells and HER2 was also performed on 
cryosections. Sections for NK cell staining were fixed in acetone at -20ºC for 7 minutes, 
air dried, sequentially treated with 0.3% H2O2 in PBS for 10 minutes, avidin/biotin 
blocking reagents (15 minutes each; Vector Laboratories), and blocking buffer (1% 
donkey serum in PBS, 20 minutes).  Sections for HER2 staining were fixed in 4% 
paraformaldehyde in PBS for 10 minutes, then permeabilized in 0.2% Triton in PBS (30 
minutes) and sequentially treated with 0.3% H2O2 in PBS (10 minutes) and avidin/biotin 
blocking reagents (15 minutes each; Vector Laboratories). Sections were then blocked 
with 1% donkey serum in PBS for 20 minutes, then treated with primary (1 hour) and 
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corresponding biotinylated secondary antibodies (45 minutes; Jackson Immunoresearch) 
diluted in 1% donkey serum in PBS.  Primary antibodies were as follows: rat anti-mouse 
Ly-49G2 (clone 4D11, BD Pharmingen) for NK cells or rabbit anti-mouse Erb2 (Abcam 
ab2428) for HER2. A Vectastain Elite ABC kit was used according to the manufacturer's 
instructions with DAB as substrate. 
To detect NK cells on formalin-fixed paraffin-embedded sections, in situ 
hybridization was performed using the ViewRNA ISH Tissue Assay Kit (Thermo Fisher) 
according to the manufacturer’s protocol.  Z-shaped probe pairs specific for mouse Ncr1 
(natural cytotoxicity triggering receptor 1, NKp46) RNA were synthesized by the kit 
manufacturer. The deposition of Fast Red precipitates indicating positive signals was 
imaged by fluorescence microscopy using a rhodamine filter set. Sections were 
counterstained with DAPI to show nuclei. 
 
ICV Herceptin® and AAV9.trastuzumab administration for quantification of trastuzumab 
in brain tissue 
AAV9.trastuzumab was diluted in PBS. 1e11 GC per Rag1-/- mouse was 
delivered ICV in a final volume of 10 µL. Two weeks later, brains were harvested.  
Herceptin® was diluted in PBS and administered ICV in a 10 µL volume at a 
dose of 15 µg/mouse brain, which is roughly equivalent to a 50 mg IT dose in humans by 
brain mass. Brains were harvested 24, 48, and 168 hours after ICV administration of 
Herceptin®. Brains were homogenized as described above in 1 mL tissue lysis buffer. 
Protein A ELISA, performed as described above, was used to determine ng/mL of 
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trastuzumab in brain homogenate. Multiplying this trastuzumab concentration by the 
homogenate volume of 1 mL yielded approximate ng trastuzumab per brain.  
 
Study Approval and Animal Welfare 
All procedures and protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Pennsylvania.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
Tables & Table Legends 
Reference
LM or 
Intraparenchymal
Dose                   
(total cumulative 
dose)
Frequency
Concurrent treatments                      
(if indicated)
MRI or Clinical 
Response 
Duration 
of 
response 
(months)
AEs/SAEs
OS 
(months)
Preusser et al. LC
5-100mg                
(250 mg)
Twice weekly IV PLD, IV trastuzumab MRI progression NR None 
1.5 
months
Hofer et al. LC
100-150mg             
(1110 mg)
Every 2-3 
weeks
IV trastuzumab CR >5.4 None 
5.4 
months
Mego et al. LC
20-40mg (180 
mg)
Weekly
IT MTX, IT cytarabine, IT 
hydrocortisone
PR
13.5 
months
Postradiation 
leukoencephalopathy, 
ischemic lesion in fronto-
temporal region of left brain 
13.5
Mego et al. LC
20-100mg              
(440 mg)
Weekly
IT MTX, IT cytarabine, IT 
hydrocortisone
PR 7.5 months None 
7.5 
months
Oliviera et al. LC
25 mg                    
(825 mg)
Weekly
IT prednisone, IT capecitabine, 
IV trastuzumab
SD 9 None 
18.4 
months
Ferrario et al. LC
20-40 mg               
(610 mg)
Weekly
IT MTX, IT cytarabine, IT 
hydrocortisone, IV 
trastuzumab, IV PLV
PR 10 G3: anemia, neutropenia >23
Colozza et al. Intraparenchymal
12.5 mg              
(287.5 mg)
Every 3 
weeks
IV trastuzumab SD 19 None >37
Allison et al. LC 20-60 mg 
Every 1-2 
weeks
Clinical 
improvement
>1 None >1
Allison et al. LC 20-60 mg
Every 1-2 
weeks
Clinical 
improvement
>3.5 None >3.5
Allison et al. LC 20-60 mg
Every 1-2 
weeks
SD --> 
progression
Not 
reported
None 
Not 
reported
Allison et al. LC 20-60 mg
Every 1-2 
weeks
SD --> 
progression
Not 
reported
None 
Not 
reported
Stemmler et al. 
2008
LC
20 mg                 
(80mg)
Twice weekly IT MTX
Clinical 
improvement 
1.3 None 1.3
Mir et al. LC
20-100 mg 
(460mg)
Every week SD 2 None 7
Shojima et al. LC
25 mg/kg               
(>150 mg/kg)
Every week PR >1.5 None >1.5
Platini et al. LC
20-25 mg              
(405-495 mg)
Every week IV paclitaxel, IV trastuzumab MRI progression 5 None >21
Stemmler et al. 
2006
LC 4-20 mg (70 mg) Twice weekly
IV trastuzumab, PO 
capecitabine 
Clinical 
improvement
5.2 None >5.2
Laufman and 
Forstoefel
LC 5-20 mg (35 mg) Over 2 weeks
IT MTX, IT Thiotepa, IV 
paclitaxel, IV trastuzumab
SD 1.5 None 2.2
Brandt et al. LC 25 mg
Every other 
day for 3 
weeks, then 
weekly
IV trastuzumab, IV 
capecitabine, IV lapatinib
Clinical 
improvement
>46 
months
None 
>46 
months
Kordbacheh et 
al.
LC
40-105 mg            
(1090 mg)
Every 1-2 
weeks
IT MTX CR >7.4 None 7.4
Lu et al. LC 5-80 mg
Twice weekly 
for one month 
then every 
two weeks
Lapatinib, IV trastuzumab 
emtansine
SD 46
Meningitis (Ommaya 
replaced)
46
Bousquet et al. Intraparenchymal 25-100 mg
Every 3 
weeks, then 
weekly, then 
every three 
days
SD >6 None >6
Dumitrescu et 
al.
LC 20-100 mg Weekly IV trastuzumab PR 2 None 2
Park et al. LC 25-50 mg Weekly IT methotrexate PR 18 None 20
Park et al. LC 25-50 mg Weekly IV trastuzumab, IV paclitaxel PR 13 None >13
Pluchart et al. LC 21mg Weekly IV trastuzumab, lapatinib PR 14 None >14
Gulia et al. LC 50-150mg
Twice weekly, 
weekly, every 
3 weeks
lapatinib, letrozole, IT 
hydrocortisone
PR 4 None 
Not 
reported
Giulia et al. LC 150mg
Every 3 
weeks, 
weekly, every 
3 days
IV trastuzumab, lapatinib, IT 
hydrocortisone
SD 7 None >7
Table 1. A summary of case reports of IT trastuzumab used to treat HER2+ BCBM.  [219-
221, 256-276]. Table adapted from [219, 257-259]. (MTX, methotrexate; OS, overall survival; CR, 
complete response; PR, partial response; SD, stable disease; AE, adverse event; SAE, serious 
adverse event; LC, leptomeningeal carcinomatosis; PO, by mouth) 
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IT Trastuzumab Clinical Trials PI Size Dose Safety Phase II study?
Expected 
completion 
dates
Clinical benefit so far?
Intrathecal Trastuzumab for 
Leptomeningeal Metastases in 
HER2+ Breast Cancer (Phase I)
Raizer et al. 
(Northwestern)
13 women with HER2 
positive BC, 1 man with 
glioblastoma, and one 
woman with anaplastic 
ependymoma
3 patients at 
10mg, 3 at 
20mg, 1 at 
40mg, 1 at 
60mg, and 7 at 
80
AEs/SAEs = 1 patient 
had grade 4 dose-
limiting toxicity 
(arachnoiditis); one 
patient had ommaya 
removed due to 
infection
Phase I/II study 
at 40 mg max 
dose in 
progress
Expected primary 
endpoint results 
3/2018, estimated 
study completion 
date 3/2019
N/A
Safety and Efficacy of Intrathecal 
Trastuzumab Administration in 
Metastatic HER2 Positive Breast 
Cancer Patients Developing 
Carcinomatous Meningitis (Phase 
I/II Study)
Gutierrez et al. 
(Institut Curie)
19 patients
30-150mg 
(aimed for 30 
ug/mL in CSF)
No >3 tox or neuro 
toxicity; maximum 
tolerated dose not 
reached; treatment 
well-tolerated in 
general
Phase II at 150 
mg dose in 
progress
Expected primary 
endpoint results 9/ 
2017, estimated 
study completion 
date 5/2018
*5 patients out of 19 
had evident clinical 
benefit      *All had 8 or 
more administrations of 
IT Herceptin® (mean 
23)              *Effective 
dose(s)  not mentioned
Intrathecal Pertuzumab and 
Trastuzumab in Patients with New 
Untreated Asymptomatic or Low 
Symptomatic Brain Metastasis in 
HER2 Positive Breast Cancer 
(Phase I/II)
Blackwell et al. 
(Duke)
36 patients
80 mg 
trastuzumab, 10-
80 mg 
pertuzumab
N/A N/A
Expected primary 
endpoint results 
2/2019, study 
complete 8/2019
N/A
 
Table 2. A summary of ongoing clinical trials using IT Herceptin® to treat HER2+ BCBM. 
(clinicaltrials.gov) 
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Figures & Figure Legends  
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Fig. 1. IT AAV9.trastuzumab tumor prophylaxis. (A) Kaplan-Meyer survival curves for mice 
that received IT AAV9.trastuzumab tumor prophylaxis, IT AAV9.2.10AmAb control treatment, or 
no treatment at least 21 days before tumor challenge. (B) Tabulated survival and statistical data 
for Fig. 1A. (C-D) Serum expression of trastuzumab and 2.10A mAb measured by protein A 
ELISA. (E) IgG transgene expression in brain tissue measured by protein A ELISA of brain 
homogenate and graphed as a percent of total protein in brain homogenate. (F)  Positive HER2 
immunohistochemistry (IHC) staining of BT474.M1.ffluc tumors from the necropsies of mice from 
Fig. 1A. 
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Fig. 2. IT AAV9.trastuzumab tumor treatment. (A) Kaplan-Meyer survival curves for mice that 
received IT AAV9.trastuzumab tumor treatment, IT AAV9.2.10AmAb control treatment, or no 
treatment 3 days after tumor challenge. (B) Tabulated survival and statistical data for Fig. 2A. 
83 
 
A
A
V
9
.2
.1
0
A
m
A
b
N
o
 t
re
a
tm
e
n
t
A
A
V
9
.t
ra
s
tu
z
u
m
a
b
Human/rhesus IgG DAPI Merge
A
A
V
9
.t
ra
s
tu
z
u
m
a
b
A
A
A
V
9
.t
ra
s
tu
z
u
m
a
b
A
A
V
9
.2
.1
0
A
m
A
b
N
o
 T
re
a
tm
e
n
t
0
2
4
6
8
1 0
T
u
m
o
r 
D
ia
m
e
te
r 
 (
m
m
)
D a y  4 7  tu m o r  d ia m e te r
n .s .
*
A
A
V
9
.t
ra
s
tu
z
u
m
a
b
A
A
V
9
.2
.1
0
A
m
A
b
 
N
o
 T
re
a
tm
e
n
t  
0 .0 0 0
0 .0 0 1
0 .0 0 2
0 .0 0 3
0 .0 0 4
D a y  4 7  b r a in  t is s u e  Ig G
%
 o
f 
to
ta
l 
p
ro
te
in
A
A
V
9
.t
ra
s
tu
z
u
m
a
b
A
A
V
9
.2
.1
0
A
m
A
b
N
o
 T
re
a
tm
e
n
t
0
1 0
2 0
3 0
D a y  0  s e ru m   Ig G
S
e
ru
m
 I
g
G
 (
u
g
/m
L
)
D
B C
500 µm
 
Fig. 3. Day 47 tumor diameter and IgG immunofluorescence microscopy. (A) IT 
AAV9.trastuzumab tumor prophylaxis yielded tumors of significantly smaller diameter than IT 
AAV9.2.10AmAb control treatment or no treatment when measured 47 days after tumor cell 
implantation (p=0.0159). (B) IgG transgene expression in brain tissue measured by protein A 
ELISA of brain homogenate and reported as a percent of total protein in brain homogenate. (C) 
Serum IgG transgene expression on the day of tumor challenge (day 0) measured by protein A 
ELISA. (D) Immunofluorescence staining for human/rhesus IgG in day 47 tumor cryosections. 
Representative HER2 IHC staining is shown in Fig. S5 
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Fig. 4. IT AAV9.trastuzumab tumor prophylaxis in NOD scid gamma mice. (A) Kaplan-Meyer 
survival curves for mice that received IT AAV9.trastuzumab tumor treatment or no treatment at 
least 21 days before tumor challenge. (B) Tabulated survival and statistical data for Fig. 4A.  
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Fig. 5. IT AAV9.trastuzumab tumor prophylaxis in the setting of continuous NK cell 
depletion. (A) Kaplan-Meyer survival curves for mice that received IT AAV9.trastuzumab tumor 
prophylaxis or IT AAV9.2.10AmAb control treatment with or without continuous NK cell depletion 
using PK136 (anti-NK1.1 antibody). (B) Tabulated survival and statistical data for Fig. 5A. (C) In 
situ hybridization for Ncr1 (NKp46) RNA (red) in formalin-fixed paraffin-embedded tumors 
harvested at necropsy from the experiment in Fig. 5A. DAPI (blue). (D) IgG transgene expression 
in brain tissue measured by protein A ELISA of brain homogenate and graphed as a percent of 
total protein in brain homogenate. (E) In situ hybridization of Ncr1 RNA in formalin-fixed paraffin-
embedded spleens harvested at necropsy. 
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Fig. 6. NK cell immunohistochemical staining of day 20 tumors. Immunohistochemical 
staining for NK cells (Ly-49G2) performed on day 20 tumor cryosections. 
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Fig. 7. IT AAV9.trastuzumab tumor prophylaxis in the setting of continuous systemic 
macrophage depletion. (A) Kaplan-Meyer survival curves for mice that received IT 
AAV9.trastuzumab tumor prophylaxis or IT AAV9.2.10AmAb control treatment with or without 
systemic macrophage depletion. (B) Tabulated survival and statistical data for Fig. 6A. (C) IgG 
transgene expression in brain tissue measured by protein A ELISA of brain homogenate and 
graphed as a percent of total protein in brain homogenate. (D) CD68 IHC staining of formalin-
fixed paraffin-embedded spleens harvested at necropsy from animals treated with liposomal PBS 
or liposomal clodronate. 
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Fig S1. Biodistribution of vector genome copies in brain. AAV9 genome copies in brain 
tissue from experiment in Fig. 1 determined by qPCR. 
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Fig S2. Trastuzumab quantified in brain tissue.  1e11 GC AAV9.trastuzumab or 15 µg 
Herceptin® in PBS was administered ICV to mice. Brains were harvested after the duration of 
time indicated for trastuzumab quantification in tissue. 
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Fig S3. Anti-IgG immunofluorescence of day 20 and day 47 tumor cryosections. (A) Green 
channel (human/rhesus IgG) overexposures of day 47 tumors (Fig. 3D) from mice that 
received IT AAV9.trastuzumab prophylaxis. (B) anti-IgG immunofluorescence staining of 
day 20 tumor cryosections.  
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Fig S4. IgG expression in brain tissue. IgG transgene expression in brain tissue from 
experiment in Fig. 4 measured by protein A ELISA of brain homogenate and graphed as 
a percent of total protein in brain homogenate.  
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Fig S5. Human HER2 IHC staining of day 47 tumors. Positive HER2 immunohistochemistry 
staining of day 47 BT474.M1.ffluc tumors from the necropsies of mice in the experiment 
in Fig. 3D. 
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